The Weekly Term Sheet (2026-W24)

The week in numbers

• $10.6B all-cash: GSK to acquire Nuvalent (Nasdaq: NUVL), a clinical-stage precision-oncology company, at $124.00 per share (about a 40% premium, roughly $9.4B net of Nuvalent's cash) via a tender offer for all Class A and Class B shares. The window's largest print by an order of magnitude and the second-largest deal in GSK's history; an equity acquisition of two near-commercial NSCLC inhibitors. GSK assumes Nuvalent's existing revenue-sharing arrangements: low-single-digit royalties payable to Royalty Pharma and Deerfield, a confirmed third-party royalty layer surviving the buyout.
• $1.25B upfront cash: Incyte to acquire Vega Therapeutics, the wholly owned Star Therapeutics subsidiary holding VGA039, a Phase 3 anti-Protein S antibody for von Willebrand disease. Ceiling up to $2.0B with sales milestones; an equity acquisition, no retained royalty.
• $1.0B cash: Johnson & Johnson to acquire Firefly Bio for the Firelink degrader-antibody-conjugate (DAC) platform in KRAS-driven solid tumours. All-cash, no disclosed milestones or retained royalty; closing targeted later in 2026.
• $700M upfront cash: Roche to Nurix Therapeutics for bexobrutideg (NX-5948), a BTK degrader, in a co-development and co-commercialisation collaboration across haematology, immunology, and neurology. Ceiling up to $2.3B with milestones, plus low- to high-teens tiered royalties to Nurix on ex-US net sales and a 50/50 US profit split. The window's lead royalty-bearing print.
• $670M IPO plus $75M Regeneron private placement (~$745M total): Parabilis Medicines priced an upsized, above-range Nasdaq IPO (PBLS), the largest ever for a venture-backed biotech, with a concurrent Regeneron private placement tied to a separate, undisclosed research collaboration. A primary equity print, no royalty origination; the Regeneron collaboration is a partnering watch item.
• ~$2.5B equity value, $900M+ combined cash: Treeline Biosciences to go public via an all-stock merger with Standard BioTools (Nasdaq: LAB), a reverse merger that lists the Bilenker / Engelman oncology company as Treeline Biosciences (ticker TRLN). Pre-merger Standard BioTools holders receive a CVR on legacy diagnostics monetisation plus an Illumina / SomaLogic earnout; Treeline's lead EZH2 inhibitor TLN-254 carries a 10 to 12.5% royalty to Hengrui.
• Up to CHF 250M committed, CHF 150M first tranche: Pharmakon Advisors (BioPharma Credit) to Idorsia, a senior secured term loan with a 5-year maturity at a fixed 7% rate, the window's only structured-finance print from a royalty- and credit-finance house on the watchlist. The first tranche refinances Idorsia's existing New Money Facility (CHF 105M drawn, due May 2027) and extends runway into 2028. Non-dilutive debt rather than a royalty monetisation.
• $135M equity plus up to $165M from Hercules Capital (including $55M royalty financing): Beren Therapeutics raised about $300M combined to fund commercial readiness for adrabetadex, a cyclodextrin therapy for infantile-onset Niemann-Pick disease type C (I-NPC), ahead of a November 17, 2026 PDUFA date. The Hercules tranche pairs senior secured debt with a $55M royalty-financing sleeve, the window's only explicit royalty layer and its second structured-finance print after Idorsia / Pharmakon.
• $175M Series E: Samsung Electronics invested $175M in Element Biosciences, a DNA-sequencing and life-science-tools company. A tools and instrumentation financing, not a therapeutic royalty event.
• $125M Series B: SonoThera closed an oversubscribed round to take its ultrasound-mediated nonviral genetic-medicine platform (RIPPLE / PORE) into the clinic in DMD and ADPKD. The window's largest venture round; a clean raise, no royalty layer.
• $99.5M committed: City Therapeutics Series B, to advance its next-generation extrahepatic RNAi platform (cityRNAs activating Argonaute-3), led by CITY-FXI in Phase 1. A clean equity raise; City is an inbound-royalty recipient on its Biogen and Bausch + Lomb out-licenses.
• $32M upfront, up to $64M total, no retained royalty: Adial Pharmaceuticals (Nasdaq: ADIL) acquired Azora Therapeutics in a stock-for-stock merger handing Azora's former equityholders majority ownership, alongside a concurrent private placement of up to $64M (about $32M upfront via pre-funded warrants at $2.7489, including conversion of assumed notes, plus up to $32M on Phase 1 initiation). Adds AT177, a colon-targeted AhR agonist for ulcerative colitis. A micro-cap reverse takeover plus PIPE, no royalty layer.
• $40M upfront, up to $1.4B ceiling, tiered royalties to Orionis: Orionis Biosciences to Novartis, a renewed and expanded multi-year molecular glue discovery collaboration using Orionis's Allo-Glue platform and AI discovery engine. Tiered royalties to Orionis on net sales of collaboration products. A privately held originator royalty in the making against a large-cap.
• $10M upfront, up to $527M total, tiered single- to double-digit royalties plus a high-teens equity option: Laekna to Vasque Bio for ex-Greater-China rights to LAE118, a PI3K-alpha pan-mutant-selective inhibitor. Up to $517M in development and sales milestones, tiered royalties, and Laekna's right to acquire up to a high-teens percentage of Vasque's stock at no extra cost (or cash in lieu). A China-outbound originator royalty with an equity kicker, extending the W23 Asia-outbound theme.
• $10M upfront, >$1B ceiling excluding royalties: AlzeCure Pharma to out-license global rights to ACD680, a gamma-secretase modulator for Alzheimer's disease, to Eli Lilly, with mid-single-digit royalties to AlzeCure on product sales. A sub-scale Swedish originator royalty; subject to Swedish foreign direct investment screening.
• EUR 7M for a 30.4% stake, no royalty: Shilpa Biocare (a Shilpa Medicare subsidiary, BSE/NSE: SHILPAMED) took a 30.4% equity stake in Barcelona-based Gate2Brain for EUR 7M (EUR 0.5M cash, EUR 5.5M in equity for services, EUR 1M project development) and became CMC, manufacturing, and regulatory partner for G2B-002, a MiniAp4 peptide shuttle delivering SN-38 across the blood-brain barrier in pediatric DIPG and pGBM (US FDA and EMA orphan drug). A strategic equity-and-services investment, no royalty layer.
• $2M upfront, quarterly royalties to ExCellThera plus milestones: Medexus to license exclusive Canadian commercialisation rights to UM171 Cell Therapy (Zemcelpro / dorocubicel) from ExCellThera and its subsidiary Cordex Biologics. A small regional commercial royalty accruing to the Canadian originator on a conditionally EU-approved cell therapy, with Cordex supplying on a cost-plus basis.
• Up to GBP 44.5M upfront and near-term, GBP 118M per target in milestones: Engitix to GSK, a research collaboration and option agreement on liver fibrosis regression targets, carrying tiered low-single-digit royalties to Engitix on future product sales. A UK originator platform royalty, earlier-stage and per-target.
• ~SEK 124M rights issue plus up to SEK 75M venture loan: Cantargia, a Lund-based IL1RAP oncology company, opened a rights issue (June 8 to 22) alongside a Fenja Capital loan facility, up to ~SEK 199M combined, to fund a nadunolimab plus daraxonrasib Phase Ib in pancreatic cancer and a hematology programme. A dilutive raise with a venture-debt sleeve, no royalty origination.
• ~NOK 300M (USD ~32M) gross: Circio Holding (OSE: CRNA) completed a warrant-exercise programme plus an underwritten private placement, taking H1 2026 proceeds to ~NOK 620M (USD ~65M) to fund the circVec circular-RNA platform to clinical proof of concept. A clean equity print, no royalty layer.
• US$36.5M (C$50M), royalty-retiring: PharmaEssentia (TWSE: 6446) closed its acquisition of 100% of FORUS Therapeutics, its Canadian BESREMi (ropeginterferon alfa-2b) licensee. Agreed April 9 and completed June 11; only the closing falls in-window. The buy-in collapses an existing downstream royalty: under the October 2024 Canada license FORUS owed PharmaEssentia double-digit percentage royalties on BESREMi net sales plus up to $107M in milestones. A third-party royalty converted into wholly owned commercial economics, the inverse of an origination.
• Undisclosed terms, Lonza platform royalty model: AmMax Bio to license Lonza's GlycoConnect, HydraSpace, and exatecan-based SYNtecan linker-payload technologies (non-exclusive) for AMB-104, an ADC in venetoclax / azacitidine-resistant AML. Terms not disclosed; Lonza's near-identical Stipple Bio license (June 4) carried upfront, milestone, and net-sales royalty terms to Lonza, marking a Basel CDMO platform-royalty model.
• Undisclosed terms, upfront and milestones to WestGene: Cartesian Therapeutics to license WestGene Biopharma's targeted LNP platform, pairing it with Cartesian's Descartes-08 mRNA payload for in-vivo mRNA CAR-T in autoimmune disease. No royalty disclosed.
• Undisclosed terms: GENESIS Pharma to expand its commercialisation of Alnylam's RNAi therapeutics into four Nordic markets. A regional distribution expansion, no disclosed royalty origination.
• Undisclosed terms, no royalty: Verge Labs (formerly Verge Genomics; San Francisco) and China-based, Bain Capital-backed Tenacia Biotechnology formed a strategic platform partnership applying Verge's multimodal human brain-tissue AI platform to prioritise targets across Tenacia's CNS pipeline. The first deal under Verge's May 2026 platform-first model. A data-and-AI collaboration, no royalty layer.
• Undisclosed terms, no royalty: Syntax Bio (Chicago) and Mayo Clinic formed an R&D collaboration to develop an allogeneic, iPSC-derived pancreatic beta-cell therapy for type 1 diabetes using Syntax's CRISPR-based Cellgorithm platform; Mayo provides pancreatic biology and preclinical functional testing and holds a financial interest. A research collaboration, no royalty layer.
• Undisclosed terms: Galmed Pharmaceuticals to acquire Colospan for the CG-100 intraluminal bypass device in colorectal anastomotic protection. A GI medtech pivot, terms not disclosed, no royalty layer.
• Undisclosed terms, royalties to BioNTech: BioNTech's planned separation from founders Ugur Sahin and Ozlem Tureci (Handelsblatt, June 8) would carve early-stage CAR-T and RiboMAB mRNA programmes into a new founder-led company, in exchange for a minority stake plus milestones and royalties to BioNTech and a RiboMAB license-back option. The Pfizer / Comirnaty profit split stays at BioNTech.
• Survodutide Phase 3 re-rate, no new capital: Boehringer Ingelheim and Zealand Pharma presented SYNCHRONIZE-1 (obesity) and SYNCHRONIZE-MASLD Phase 3 data at ADA 2026 (Sun June 7), published in NEJM and Nature Medicine. Up to a 16.6% average weight loss at 76 weeks; re-rates Zealand's high-single-digit to low-double-digit royalty plus up to EUR 315M in outstanding milestones.
• Elecoglipron Phase 2b re-rate, no new capital: AstraZeneca presented positive VISTA (obesity) and SOLSTICE (type 2 diabetes) Phase 2b data on elecoglipron (AZD5004 / ECC5004), supporting global Phase 3 initiation. Re-rates Eccogene's tiered royalty plus up to ~$1.825B in outstanding milestones on AstraZeneca's ex-China net sales.
• Anbenitamab Phase 3 breast cancer topline, no new capital: Alphamab Oncology's anbenitamab (KN026), co-developed with CSPC subsidiary JMT-Bio, read out positive Phase 3 breast cancer data with CSPC's albumin-bound docetaxel (HB1801). A China-domestic co-development with no disclosed tradable third-party royalty held by an independent originator.
• Vopimetostat plus daraxonrasib PDAC re-rate, no new capital: Tango Therapeutics (Nasdaq: TNGX) reported initial Phase 1/2 data for its PRMT5 inhibitor vopimetostat combined with Revolution Medicines' RAS(ON) inhibitor daraxonrasib in MTAP-deleted, RAS-mutant metastatic PDAC: a 92% objective response rate (11 of 12 response-evaluable patients, 9 of 11 confirmed) and a 90% six-month PFS rate, supporting Phase 3 in first-line disease. Incremental de-risking of the commercial base behind Royalty Pharma's up to $1.25B synthetic royalty plus up to $750M senior secured loan on daraxonrasib (June 2025); the primary daraxonrasib re-rate was the April 2026 RASolute 302 monotherapy Phase 3, which triggered the second $250M royalty tranche. An RPRX back-book position, not a new origination.
• Zasocitinib Phase 3 head-to-head win, no new capital: Takeda (NYSE: TAK) reported LATITUDE Atlas topline data showing zasocitinib (TAK-279) statistically superior to deucravacitinib on PASI 100 at week 16 in moderate-to-severe plaque psoriasis (more than 35% complete skin clearance, more than 2.5 times the comparator). Advances the oral TYK2 inhibitor Takeda acquired from Nimbus Therapeutics in 2022; Nimbus holds up to $2B in contingent sales milestones (two $1B tranches at $4B and $5B in annual net sales), not a running royalty.
• Bondholder restructuring, no new external capital: Magle Chemoswed (Magle Group) reached agreement in principle on key restructuring terms with an ad hoc group holding ~70% of its SEK 350M senior secured bonds (June 11), a debt-for-control workout under which bondholders may take control. A distressed restructuring, no royalty content.
• Fund first close, size undisclosed: Star51 Capital held the first close of its inaugural medtech-and-AI "ecosystem" venture fund, anchored by Abbott and Mayo Clinic with a roster of medtech-operator LPs (June 11). A supply-side capital-formation event, not a deal; relevant as a read on dedicated medtech / device capital, in CFC's device scope but not a royalty origination.
• Clinical and regulatory prints, no royalty layer: Sanofi's anti-C1s antibody SAR445088 Phase 3 in CIDP discontinued for lack of efficacy (June 10); FDA RMAT for a CD22-targeting allogeneic CAR-T (lasme-cel) in r/r B-ALL (June 9); FDA orphan drug designation for Tris Pharma's once-nightly oxybate TRN-257 in idiopathic hypersomnia (June 10); FDA Complete Response Letter to Camurus for CAM2029 (Oclaiz) in acromegaly (June 10), tied to a third-party manufacturer's cGMP observations rather than efficacy or safety.

M&A and major licensing:

• GSK / Nuvalent acquisition (Tue June 9): $10.6B all-cash tender offer at $124.00 per share (about a 40% premium, ~$9.4B net of cash) for clinical-stage precision-oncology company Nuvalent and its two near-commercial NSCLC inhibitors, zidesamtinib (ROS1) and neladalkib (ALK); GSK's third 2026 buyout under CEO Luke Miels and the second-largest deal in its history. An equity acquisition; GSK assumes Nuvalent's existing low-single-digit royalties payable to Royalty Pharma and Deerfield (see M&A and Restructuring)
• Incyte / Vega Therapeutics (Star Therapeutics) acquisition (Mon June 8): $1.25B upfront, up to $2.0B with sales milestones; an equity acquisition of the Star subsidiary holding VGA039, no retained royalty; closing targeted Q3 2026 subject to HSR clearance (see M&A and Restructuring)
• Roche / Nurix Therapeutics bexobrutideg collaboration (Mon June 8): $700M upfront, up to $2.3B with milestones, plus low- to high-teens tiered royalties to Nurix on ex-US net sales; 60/40 Roche/Nurix development cost share and a 50/50 US profit split (see BD Origination and Licensing)
• Johnson & Johnson / Firefly Bio acquisition (Mon June 8): $1.0B all-cash acquisition of the Firelink degrader-antibody-conjugate (DAC) platform targeting KRAS-driven solid tumours; preclinical-stage, no disclosed milestones or retained royalty (see M&A and Restructuring)
• Galmed Pharmaceuticals / Colospan acquisition (Mon June 8): definitive agreement for the CG-100 intraluminal bypass device in colorectal anastomotic protection; terms undisclosed, a GI medtech pivot, no royalty layer (see M&A and Restructuring)
• Treeline Biosciences / Standard BioTools reverse merger (Mon June 8): all-stock merger taking private oncology company Treeline public via Standard BioTools (Nasdaq: LAB); ~$2.5B Treeline equity value, $900M+ combined cash; CVR to pre-merger holders plus an Illumina / SomaLogic earnout; lead EZH2 inhibitor TLN-254 in-licensed from Hengrui (10 to 12.5% royalty) (see M&A and Restructuring)
• BioNTech / founders mRNA carve-out and separation (Handelsblatt Mon June 8): planned transfer of BioNTech's early-stage CAR-T and RiboMAB programmes to a new founder-led company, in exchange for a minority stake plus milestones and royalties to BioNTech and a RiboMAB license-back option; binding agreement targeted end of H1 2026 (see M&A and Restructuring)
• Magle Group bondholder restructuring (Thu June 11): agreement in principle on key restructuring terms with an ad hoc group holding ~70% of Magle Chemoswed's SEK 350M senior secured bonds; a debt-for-control workout under which bondholders may take control. A distressed restructuring, no royalty content (see M&A and Restructuring)
• PharmaEssentia / FORUS Therapeutics acquisition (closed Thu June 11; agreed April 9): US$36.5M (C$50M) acquisition of 100% of FORUS, PharmaEssentia's Canadian BESREMi licensee since October 2024. Retires FORUS's downstream royalty: under the Oct 2024 Canada license FORUS owed PharmaEssentia double-digit percentage royalties on BESREMi net sales plus up to $107M in milestones, now folded into wholly owned economics. A royalty-eliminating in-licensee buy-in, not a new origination (see M&A and Restructuring)
• Adial Pharmaceuticals / Azora Therapeutics acquisition and financing (Thu June 11): all-stock acquisition of Azora Therapeutics (lead AT177, a colon-targeted AhR agonist for ulcerative colitis), with Azora's former equityholders taking majority ownership, alongside a concurrent private placement of up to $64M (about $32M upfront via pre-funded warrants at $2.7489 including conversion of assumed notes, and up to $32M on Phase 1 initiation). A micro-cap reverse takeover with a PIPE, no retained third-party royalty; Lucid Capital Markets acted as placement agent (see M&A and Restructuring)

Royalty-bearing license-outs and platform layers (upfront + milestones + tiered royalties):

• Roche / Nurix bexobrutideg (Mon June 8): Nurix (San Francisco) grants Roche co-development and ex-US commercialisation rights to the BTK degrader bexobrutideg, retaining low- to high-teens tiered royalties on Roche's ex-US net sales alongside a 50/50 US profit split and a 40% development cost share. The royalty is the tradable piece (see BD Origination and Licensing)
• Orionis Biosciences / Novartis molecular glue collaboration (Tue June 10): $40M upfront, up to $1.4B in milestones, plus tiered royalties to Orionis on net sales of collaboration products. A renewal and expansion of the 2020 pact, deploying Orionis's Allo-Glue platform; the royalty accrues to a privately held, clinical-stage originator (see BD Origination and Licensing)
• Laekna / Vasque Bio LAE118 ex-China out-licence (Tue June 9): $10M non-refundable upfront, up to $517M in milestones (up to $527M total), tiered single- to double-digit royalties, plus Laekna's right to acquire up to a high-teens percentage of Vasque Bio common stock at no extra cost. A China-outbound originator royalty plus equity kicker (see BD Origination and Licensing)
• AlzeCure Pharma / Eli Lilly ACD680 (Tue June 9): AlzeCure (Sweden) grants Lilly global rights to the gamma-secretase modulator ACD680 for $10M upfront, milestones exceeding $1B excluding royalties, and mid-single-digit royalties; subject to Swedish FDI screening. A clean small-originator stream (see BD Origination and Licensing)
• Medexus / ExCellThera + Cordex Zemcelpro Canada license and supply (Tue June 9): $2M upfront, quarterly royalties to ExCellThera on Canadian net sales, and one-time milestones, with Cordex managing the Phase 3 trial and supplying on a cost-plus basis. A royalty-bearing in-licence of a conditionally EU-approved cell therapy (see BD Origination and Licensing)
• Engitix / GSK liver fibrosis collaboration (Mon June 8): up to GBP 44.5M upfront and near-term, up to GBP 118M per target in milestones, and tiered low-single-digit royalties to Engitix; GSK holds the option to license. An earlier-stage, per-target platform royalty (see BD Origination and Licensing)
• AmMax Bio / Lonza ADC linker-payload license (Tue June 9): non-exclusive access to Lonza's GlycoConnect, HydraSpace, and SYNtecan linker-payload technologies for AMB-104. Terms undisclosed; Lonza's near-identical Stipple Bio license one week earlier carried net-sales royalties to Lonza, indicating a CDMO platform-royalty model from a Basel licensor (see BD Origination and Licensing)

Structured finance and non-dilutive debt:

• Pharmakon Advisors (BioPharma Credit) / Idorsia senior secured term loan (Tue June 9): up to CHF 250M, 5-year maturity, fixed 7% rate; first tranche CHF 150M at closing, refinancing the existing New Money Facility and extending runway into 2028. Senior secured debt rather than a royalty monetisation, the window's one structured-finance print from a watchlist house (see Structured Finance and Non-Dilutive Debt)
• Beren Therapeutics / Hercules Capital $300M equity and royalty-backed financing (Wed June 10): $135M equity (Wellington Partners, JIC VGI, Founders Fund, Narya Capital, Eisai, others) plus up to $165M from Hercules Capital, structured as senior secured debt and $55M of royalty financing, to fund commercial readiness for adrabetadex (I-NPC) ahead of a Nov 17, 2026 PDUFA date. The royalty-financing sleeve is the tradable piece and the window's only pre-commercial royalty layer (see Structured Finance and Non-Dilutive Debt)

Financings (no royalty origination today):

• Parabilis Medicines $670M IPO plus $75M Regeneron private placement (priced Tue June 9, trading Wed June 10): 33.5M shares at $20 (above range), $670M gross, plus a 5.025M-share overallotment (up to ~$770M); a concurrent Regeneron placement of ~4.17M shares at $18, ~$75M, tied to a separate research collaboration. The largest IPO in venture-backed biotech history; funds the Helicon peptide platform and lead Wnt / beta-catenin inhibitor zolucatide. The Regeneron collaboration is an undisclosed-terms watch item (see Financings)
• SonoThera $125M Series B (Wed June 10): oversubscribed round led by Vida Ventures with ARK Invest, CureDuchenne Ventures, Leaps by Bayer, Otsuka, SymBiosis, UCB Ventures, Vivo Capital, and existing backers, to take the RIPPLE / PORE platform into the clinic in DMD and ADPKD. The window's largest venture round (see Financings)
• City Therapeutics $99.5M Series B (Mon June 8): co-led by Viking Global and Sofinnova with Casdin, NYBC Ventures, and existing backers, to advance the extrahepatic RNAi platform (cityRNAs / Argonaute-3) led by CITY-FXI in Phase 1. City is an inbound-royalty recipient on its Biogen and Bausch + Lomb out-licenses (see Financings)
• Element Biosciences $175M Series E (Samsung Electronics) (Tue June 9): Samsung Electronics invested $175M in the DNA-sequencing and life-science-tools company. A tools and instrumentation financing, not a therapeutic royalty event (see Financings)
• Cantargia ~SEK 124M rights issue plus up to SEK 75M Fenja Capital loan (subscription June 8 to 22): up to ~SEK 199M combined, ~60% covered by commitments (DNB Bank guaranteeing SEK 72.6M), to fund a nadunolimab plus daraxonrasib Phase Ib in pancreatic cancer. A dilutive raise with a venture-debt sleeve (see Financings)
• Circio Holding ~NOK 300M warrant exercise and private placement (Tue June 9): NOK 300M gross (NOK 213M from warrant exercises, NOK 87M from an underwriting commitment), taking H1 2026 proceeds to ~NOK 620M (USD ~65M) to advance the circVec circular-RNA platform to clinical proof of concept. A clean equity print, no royalty layer (see Financings)
• VERAXA Biotech / Voyager Acquisition Corp Nasdaq debut (closing June 10, trading June 11): completion of the de-SPAC (business combination agreement dated April 22, 2025) for the Heidelberg and Zurich ADC and BiTAC T-cell-engager developer; trades as VRXA (warrants VRXAW). Supported by a $27.5M senior secured note (issued at 87.5% of par, ~$24.2M net) and a $50M Lincoln Park Capital equity line, both signed May 27. The in-window event is the listing; the capital was arranged pre-window, no royalty layer (see Financings)
• Edesa Biotech ~$3.5M private placement (Wed June 10, announced June 11): 729,241 common shares at $4.69 (outside investors) and $5.21 (CEO), placed without an underwriter or placement agent, to fund the paridiprubart vitiligo programme and working capital; close expected about June 15. A clean micro-cap equity print, no royalty layer (see Financings)
• Shilpa Biocare / Gate2Brain EUR 7M strategic equity stake (Mon June 8; regulatory filing June 3): Shilpa Biocare (a Shilpa Medicare subsidiary) acquires a 30.4% stake in Barcelona-based Gate2Brain for EUR 7M (EUR 0.5M cash, EUR 5.5M in equity for services, EUR 1M project development) and becomes CMC, manufacturing, and regulatory partner for G2B-002 (MiniAp4 peptide shuttle delivering SN-38; pediatric DIPG and pGBM; US FDA and EMA orphan drug). A strategic equity-and-services investment into a private originator, no royalty layer (see Financings)

Fund formation (capital raised by GPs, not companies):

• Star51 Capital inaugural medtech venture fund first close (Thu June 11): first close of an operator-led medtech-and-AI "ecosystem" fund anchored by Abbott and Mayo Clinic, with medtech-operator LPs; targets early and growth-stage interventional therapies, diagnostics, monitoring, and healthcare digitalization across the US, Europe, and the Middle East. Size undisclosed; a supply-side capital-formation event in CFC's device scope, not a royalty origination (see Funds and Capital Formation)

Royalty re-ratings (no new capital):

• Boehringer Ingelheim / Zealand Pharma survodutide SYNCHRONIZE-1 and SYNCHRONIZE-MASLD Phase 3 (Sun June 7): up to a 16.6% average weight loss at 76 weeks in obesity (SYNCHRONIZE-1) and met MASLD endpoints (SYNCHRONIZE-MASLD), at ADA 2026, published in NEJM and Nature Medicine; re-rates Zealand's high-single-digit to low-double-digit royalty plus up to EUR 315M in outstanding milestones (see Survodutide and Elecoglipron Royalty Re-Rates)
• AstraZeneca / Eccogene elecoglipron VISTA and SOLSTICE Phase 2b (ADA 2026): positive Phase 2b obesity (VISTA) and type 2 diabetes (SOLSTICE) data on the oral GLP-1 receptor agonist elecoglipron, supporting global Phase 3 initiation; re-rates Eccogene's tiered royalty plus up to ~$1.825B in outstanding milestones on AstraZeneca's ex-China net sales (see Survodutide and Elecoglipron Royalty Re-Rates)
• Alphamab Oncology anbenitamab (KN026) Phase 3 breast cancer topline (Thu June 11): positive Phase 3 data for the anti-HER2 bispecific with CSPC's albumin-bound docetaxel (HB1801) in breast cancer; co-developed with CSPC subsidiary JMT-Bio. A China-domestic co-development with no disclosed tradable third-party royalty held by an independent originator
• Tango Therapeutics / Revolution Medicines vopimetostat plus daraxonrasib Phase 1/2 (PDAC) (Mon June 8): 92% objective response rate (11 of 12 response-evaluable patients, 9 of 11 confirmed) and a 90% six-month PFS rate in MTAP-deleted, RAS-mutant metastatic PDAC, supporting Phase 3 in first-line disease; incrementally de-risks the commercial base behind Royalty Pharma's up to $1.25B synthetic royalty plus up to $750M senior secured loan on Revolution Medicines' daraxonrasib (June 2025). The primary daraxonrasib re-rate was the April 2026 RASolute 302 monotherapy Phase 3, which triggered the second $250M tranche; an RPRX back-book position (see Daraxonrasib and Zasocitinib Re-Rates)
• Takeda zasocitinib (TAK-279) LATITUDE Atlas Phase 3 head-to-head (Thu June 11): zasocitinib statistically superior to deucravacitinib on PASI 100 at week 16 in moderate-to-severe plaque psoriasis (more than 35% complete skin clearance, more than 2.5 times the comparator); advances the oral TYK2 inhibitor Takeda acquired from Nimbus Therapeutics in 2022. Nimbus holds up to $2B in contingent sales milestones (two $1B tranches at $4B and $5B in annual net sales), not a running royalty (see Daraxonrasib and Zasocitinib Re-Rates)

Clinical and regulatory:

• Cartesian Therapeutics / WestGene Biopharma in-vivo CAR-T license (Tue June 9): Cartesian (Nasdaq: RNAC) pairs its Descartes-08 mRNA payload with WestGene's targeted LNP platform for in-vivo mRNA CAR-T in autoimmune disease (Phase 1 in myasthenia gravis targeted 2H 2026). WestGene receives an upfront and milestones; no royalty disclosed
• GENESIS Pharma / Alnylam Nordic commercialisation expansion (Wed June 10): GENESIS (Athens) adds Denmark, Finland, Norway, and Sweden to commercialise Alnylam's RNAi therapeutics; undisclosed terms, no disclosed royalty origination
• Verge Labs / Tenacia Biotechnology CNS platform partnership (Tue June 9): Verge Labs (San Francisco; formerly Verge Genomics) applies its multimodal human brain-tissue AI platform to prioritise targets across the CNS pipeline of China-based, Bain Capital-backed Tenacia Biotechnology; the first deal under Verge's May 2026 platform-first model. Terms undisclosed, no royalty layer
• Syntax Bio / Mayo Clinic type 1 diabetes cell therapy collaboration (Tue June 9): R&D collaboration to develop an allogeneic, iPSC-derived pancreatic beta-cell therapy for type 1 diabetes using Syntax's CRISPR-based Cellgorithm platform; Mayo provides pancreatic biology and preclinical functional testing and holds a financial interest. Terms undisclosed, no royalty layer
• Sanofi SAR445088 Phase 3 in CIDP discontinued (June 9 to 10): the anti-C1s monoclonal antibody was stopped for lack of efficacy at interim analysis; a negative readout, no royalty content
• FDA RMAT designation for a CD22-targeting allogeneic CAR-T (lasme-cel) (Tue June 9): in r/r B-ALL; a regulatory designation, no financing or royalty layer
• FDA orphan drug designation for Tris Pharma's once-nightly oxybate (TRN-257) (Wed June 10): in idiopathic hypersomnia; a regulatory designation, no financing or royalty layer
• FDA Complete Response Letter to Camurus for CAM2029 (Oclaiz) in acromegaly (Wed June 10): the CRL relates to observations from a September 2024 cGMP inspection at a third-party manufacturer, not to clinical efficacy or safety; resubmission targeted near term, with the EU and UK already approved (Oczyesa). A regulatory setback, no royalty layer

Window totals

The window's cash is overwhelmingly M&A, concentrated in the GSK / Nuvalent print.

• M&A cash: ~$12.85B upfront (~$13.6B at ceilings) across three disclosed acquisitions: GSK / Nuvalent $10.6B all-cash, Incyte / Vega $1.25B upfront (up to $2.0B), J&J / Firefly $1.0B all-cash. Plus the Treeline / Standard BioTools all-stock reverse merger (~$2.5B equity value, $900M+ combined cash) and two undisclosed-terms events (Galmed / Colospan, BioNTech founder carve-out). Separately, PharmaEssentia / FORUS closed in-window (US$36.5M, agreed April 9), a royalty-retiring in-licensee buy-in not summed into the headline because the agreement predates the window. The Adial / Azora acquisition (Thu June 11) is all-stock with a concurrent private placement of up to $64M ($32M upfront), a micro-cap reverse takeover not summed into M&A cash.
• Royalty-bearing originations: 7 license-outs and platform layers carrying future third-party royalties, ~$822M in disclosed upfronts (Roche / Nurix $700M, Orionis / Novartis $40M, Laekna / Vasque $10M, AlzeCure / Lilly $10M, Engitix / GSK up to GBP 44.5M near-term, Medexus / ExCellThera $2M), headline value up to ~$5.2B+ excluding per-target and undisclosed terms (AmMax / Lonza). None is a present aggregator purchase; all are forward streams.
• Structured finance and non-dilutive debt: 2 prints, ~$300M of capacity at Beren (incl. a $55M Hercules royalty-financing sleeve, the window's only explicit royalty layer) plus up to CHF 250M at Idorsia (CHF 150M funded). Debt and pre-commercial royalty financing, not royalty paper traded.
• Equity financings: ~$1.2B gross across eight raises with no royalty origination: Parabilis ~$745M (incl. $75M Regeneron), Element $175M, SonoThera $125M, City $99.5M, Circio ~NOK 300M (USD ~32M), Cantargia ~SEK 199M (USD ~21M), Edesa ~$3.5M, and Shilpa Biocare's EUR 7M (USD ~7.5M) strategic stake in Gate2Brain. VERAXA's de-SPAC Nasdaq listing also completed in-window (VRXA), backed by a $27.5M senior secured note and a $50M equity line arranged May 27, not counted as in-window origination.
• Royalty re-rates (no new capital): 5 readouts: survodutide (Zealand), elecoglipron (Eccogene), anbenitamab (China-domestic co-development), the Tango / Revolution vopimetostat plus daraxonrasib PDAC combination (incrementally de-risking Royalty Pharma's daraxonrasib synthetic royalty, an RPRX back-book position), and Takeda's zasocitinib head-to-head Phase 3 (advancing Nimbus's contingent sales milestones, not a running royalty).
• Fund formation: 1 first close, Star51 Capital's inaugural medtech-and-AI fund (Abbott and Mayo Clinic anchors), size undisclosed. A GP-level capital-formation event, not summed into deal value.
• Royalty paper purchased by an aggregator this window: none. Net originated-and-traded royalty total = $0; the week's royalty content is forward originations and one pre-commercial royalty-financing sleeve.

Excluded from deal-value totals

Transaction	Treatment
GSK / Nuvalent	Equity acquisition of internally discovered precision-oncology assets; GSK assumes Nuvalent's existing low-single-digit royalties payable to Royalty Pharma and Deerfield. Logged as M&A, the window's largest cash print; the assumed RPRX and Deerfield streams are a live back-book royalty layer, not newly originated paper
Incyte / Vega; J&J / Firefly Bio	Equity acquisitions with no retained third-party royalty; logged as M&A, not royalty paper. The VGA039 rare pediatric disease designation is a potential PRV source, a tradable asset but not a royalty
Galmed / Colospan	Medtech combination, no royalty layer, undisclosed terms
Treeline / Standard BioTools	Corporate combination and going-public transaction, not a royalty origination, though it carries an upstream Hengrui royalty on TLN-254 and a CVR to pre-merger holders
PharmaEssentia / FORUS	Royalty-retiring acquisition of an in-licensee, closing of an April 9 agreement; removes a downstream Canadian BESREMi royalty rather than originating one. Logged as M&A, not summed (announced pre-window)
Adial / Azora	All-stock acquisition with a concurrent up-to-$64M private placement ($32M upfront); micro-cap reverse takeover, no retained third-party royalty
Shilpa Biocare / Gate2Brain	Strategic 30.4% equity stake (EUR 7M) plus CMC, manufacturing, and regulatory partnership; investment into a private originator, no royalty layer
Parabilis IPO; SonoThera, City, Element / Samsung rounds	Primary equity raises, not royalty paper purchased by an aggregator
Roche / Nurix, AlzeCure / Lilly, Engitix / GSK, Orionis / Novartis, Laekna / Vasque, Medexus / ExCellThera, AmMax / Lonza royalties; BioNTech inbound stream	Future originations rather than present aggregator purchases
Cartesian / WestGene; GENESIS / Alnylam; Verge / Tenacia; Syntax / Mayo	No disclosed royalty
Idorsia / Pharmakon facility	Senior secured debt, not royalty paper
Beren / Hercules Capital financing	Equity plus senior secured debt and a $55M royalty-financing sleeve; the royalty layer is a forward stream, not an aggregator purchase today
Cantargia rights issue; Circio warrant exercise	Dilutive equity (Cantargia with a venture-debt sleeve), no royalty origination
VERAXA / Voyager de-SPAC	Nasdaq listing completion; business combination agreed April 2025, financing arranged May 27. In-window listing only, no royalty origination
Edesa private placement	Small primary equity raise (~$3.5M), no royalty layer
Magle Group bondholder restructuring	Distressed debt-for-control workout, no royalty content
Star51 Capital fund first close	GP-level capital formation, not a company transaction or royalty origination; tracked for LP-landscape intelligence only
Survodutide, elecoglipron, anbenitamab, vopimetostat plus daraxonrasib, zasocitinib readouts	No new capital; survodutide and elecoglipron re-rate existing Zealand and Eccogene royalties, the Tango / Revolution combination incrementally de-risks Royalty Pharma's daraxonrasib synthetic royalty (an RPRX back-book position), Takeda's zasocitinib advances Nimbus's contingent sales milestones rather than a running royalty, and anbenitamab re-rates a China-domestic co-development rather than a tradable third-party royalty

---

M&A and Restructuring

Eight corporate events anchor this section. The GSK acquisition of Nuvalent, $10.6B all-cash, is the window's largest print and the second-largest deal in GSK's history, an equity acquisition of internally discovered precision-oncology assets with no disclosed third-party royalty. The Incyte acquisition of Vega Therapeutics, up to $2.0B, is an equity acquisition, so Star retains no running royalty on VGA039. The Johnson & Johnson acquisition of Firefly Bio, $1.0B all-cash, is a preclinical platform purchase with no disclosed retained royalty.

The smaller Galmed / Colospan combination is a GI medtech acquisition with undisclosed terms. Two further events carry royalty content: the Treeline Biosciences / Standard BioTools reverse merger carries an upstream Hengrui royalty plus a CVR, and BioNTech's planned founder separation would route a milestone-and-royalty stream back to BioNTech.

A seventh, the Magle Group bondholder restructuring, is a distressed debt-for-control workout with no royalty content. An eighth, the Adial / Azora acquisition, is an all-stock takeover paired with an up-to-$64M private placement, a micro-cap reverse takeover with no retained third-party royalty.

GSK / Nuvalent: NSCLC Precision-Oncology Acquisition, $10.6B All-Cash (Tue June 9)

GSK plc (LSE / NYSE: GSK) entered a definitive agreement to acquire Nuvalent, Inc. (Nasdaq: NUVL; Cambridge, MA; founded 2017), a clinical-stage precision-oncology company, for $124.00 per share in cash, an aggregate equity value of about $10.6B (£8.0B), roughly $9.4B net of Nuvalent's ~$1.3B cash. GSK will commence a tender offer for all outstanding Class A and Class B common stock within 10 business days, with closing targeted for Q3 2026 (GSK release; GSK 6-K, SEC).

The $124.00 price is about a 40% premium to Nuvalent's prior close (shares rose ~39% to $123.25 on the news). The deal centres on two late-stage, potential best-in-class NSCLC inhibitors discovered on Nuvalent's own structure-based chemistry platform: zidesamtinib (NVL-520), a ROS1-selective inhibitor with an FDA target action date of September 18, 2026, and neladalkib (NVL-655), an ALK-selective inhibitor with a target date of November 27, 2026. Both hold FDA Breakthrough Therapy and Orphan Drug designations, with pivotal data at IASLC WCLC 2025 and ASCO 2026; the pipeline also includes the earlier-stage NVL-330 (HER2). Analyst peak-sales estimates for the pair range widely, from ~$823M (CGS International, FY2029) to up to ~$4B combined (BofA). GSK frames the deal as accretive to sales and core operating profit in 2027 and core EPS in 2029, a platform for expansion with its B7-H3 ADC Ris-Rez, and an offset to the 2028 loss of exclusivity on dolutegravir, with no change to 2026 guidance. It is GSK's third 2026 acquisition under CEO Luke Miels, after Rapt Therapeutics ($2.2B, January) and 35Pharma ($950M, February), and the second-largest in GSK's history.

Term	Detail
Acquirer	GSK plc (LSE / NYSE: GSK; CEO Luke Miels)
Target	Nuvalent, Inc. (Nasdaq: NUVL; Cambridge, MA; founded 2017; CEO James Porter; structure-based precision oncology)
Structure	All-cash tender offer for all Class A and Class B common stock at $124.00 per share, commencing within 10 business days
Economics	~$10.6B equity value (£8.0B); ~$9.4B net of cash; about a 40% premium; $350.475M termination fee
Funding	New and existing debt facilities plus cash
Lead assets	Zidesamtinib (NVL-520; ROS1; PDUFA Sept 18, 2026) and neladalkib (NVL-655; ALK; PDUFA Nov 27, 2026), both Breakthrough Therapy and Orphan Drug; plus early-stage NVL-330 (HER2)
Peak-sales range	~$823M (CGS International, FY2029) to up to ~$4B combined (BofA)
Strategic rationale	Entry into targeted lung cancer; platform for GSK's Ris-Rez B7-H3 ADC; offsets 2028 dolutegravir HIV loss of exclusivity; supports the £40B-by-2031 sales goal
Condition / timing	Subject to tender conditions, HSR and other regulatory clearances; Nuvalent board recommends acceptance; closing targeted Q3 2026
Advisers	Leerink Partners and Citigroup (financial) and Davis Polk & Wardwell and Slaughter and May (legal) to GSK; Centerview Partners and Jefferies (financial), Ropes & Gray (legal) and Sidley Austin (corporate) to Nuvalent
Date	Tue June 9, 2026

Royalty read
Structure	Equity acquisition; GSK buys the assets outright via tender offer
Tradable element	Zidesamtinib and neladalkib are internally discovered from Nuvalent's chemistry platform, but the assets are not royalty-free: GSK assumes Nuvalent's existing revenue-sharing arrangements, low-single-digit royalties payable to Royalty Pharma and Deerfield, which survive the acquisition and accrue on GSK's net sales. Deerfield's stream traces to its 2017 founding-investor seeding of Nuvalent (sole Series A funder); Royalty Pharma holds a separate low-single-digit stream. A Guardant Health companion-diagnostics collaboration (April 2026) also travels with the assets but is a commercial pact, not a royalty
Read	The window's largest cash print, removing two near-commercial precision-oncology assets from the out-licensing universe into a wholly owned franchise; logged as M&A, but it carries a live Royalty Pharma (and Deerfield) low-single-digit royalty on two NSCLC inhibitors entering commercial review, an RPRX back-book position rather than new origination

Incyte / Vega Therapeutics: VGA039 Bleeding-Disorder Acquisition, Up to $2.0B (Mon June 8)

Incyte (Nasdaq: INCY; Wilmington, DE) entered a definitive agreement to acquire Vega Therapeutics, Inc., a wholly owned subsidiary of Star Therapeutics, LLC (South San Francisco, CA), for $1.25B upfront, with up to $750M in additional payments on sales milestones, up to $2.0B total (Incyte 8-K exhibit, SEC).

The acquisition adds VGA039, an investigational anti-Protein S monoclonal antibody in Phase 3 pivotal development for von Willebrand disease (VWD), the most common inherited bleeding disorder (~135,000 diagnosed US patients). It is positioned as a potential first subcutaneous, once-monthly prophylactic therapy for VWD, against current factor-replacement regimens requiring two to three IV infusions a week.

Term	Detail
Acquirer	Incyte Corporation (Nasdaq: INCY; Wilmington, DE; CEO Bill Meury)
Seller	Star Therapeutics, LLC (South San Francisco, CA; Founder and CEO Adam Rosenthal), selling its wholly owned subsidiary Vega Therapeutics, Inc.
Asset	VGA039: investigational anti-Protein S monoclonal antibody; subcutaneous, once-monthly
Lead indication / stage	Von Willebrand disease (all types); Phase 3 VIVID-6 (NCT07115004)
Regulatory designations	FDA Breakthrough Therapy, Fast Track, orphan drug, and rare pediatric disease designations
Structure	Equity acquisition; expected ~$1.25B R&D charge in Q3 and FY2026
Economics	$1.25B upfront plus up to $750M sales milestones (up to $2.0B); no retained Star royalty
Condition	Subject to HSR clearance; closing targeted Q3 2026
Advisers	Lazard and Goodwin Procter to Incyte; Evercore, Morgan Stanley, and Fenwick & West to Star
Date	Mon June 8, 2026

Royalty read
Structure	Equity acquisition; Incyte buys the asset outright, Star retains no running royalty on VGA039
Tradable element	VGA039 rare pediatric disease designation, a potential priority review voucher on approval; a sellable asset, not a royalty stream
Read	Removes a private clinical-stage asset from the out-licensing universe into a wholly owned franchise; the largest disclosed cash print of the window

Johnson & Johnson / Firefly Bio: Firelink Degrader-Antibody-Conjugate Platform, $1.0B Cash (Mon June 8)

Johnson & Johnson (NYSE: JNJ) entered a definitive agreement to acquire Firefly Bio, Inc. (South San Francisco, CA; privately held) for $1.0B in cash, adding the proprietary Firelink degrader-antibody-conjugate (DAC) platform and preclinical candidates targeting KRAS-driven solid tumours (J&J release).

The Firelink platform conjugates targeted protein degraders to antibodies, a next-generation variant of the ADC format. The deal is all-cash with no disclosed milestone tail; closing targeted later in 2026.

Term	Detail
Acquirer	Johnson & Johnson (NYSE: JNJ)
Seller	Firefly Bio, Inc. (South San Francisco, CA; privately held; venture-backed)
Asset / platform	Firelink degrader-antibody-conjugate (DAC) platform; preclinical candidates in KRAS-driven solid tumours
Stage	Preclinical
Economics	$1.0B all-cash; no disclosed milestones or retained royalty
Condition	Subject to regulatory clearance; closing targeted later in 2026
Date	Mon June 8, 2026

Royalty read
Structure	All-cash platform acquisition; no disclosed milestone or royalty tail
IP note	Firefly's degrader and conjugation IP may rest on in-licensed academic or platform components, but none was disclosed; no tradable third-party royalty to log today
Read	A platform consolidated into J&J rather than a stream created; a second degrader-modality print alongside the Roche / Nurix BTK degrader

Galmed Pharmaceuticals / Colospan: CG-100 Anastomotic-Protection Device, Terms Undisclosed (Mon June 8)

Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD; Tel Aviv) entered a definitive agreement to acquire Colospan Ltd. (Israel; privately held), maker of the CG-100 intraluminal bypass device, which protects colorectal anastomoses and can reduce the need for a diverting stoma (PharmExec roundup).

Financial terms were not disclosed. Colospan becomes a wholly owned Galmed subsidiary, a medtech pivot. CG-100 carries FDA Breakthrough Device Designation and a CE mark under EU MDR, with a US pivotal IDE trial ongoing.

Term	Detail
Acquirer	Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD; Tel Aviv)
Seller	Colospan Ltd. (Israel; privately held)
Asset	CG-100: intraluminal bypass device for protecting colorectal anastomoses and reducing diverting stomas
Regulatory status	FDA Breakthrough Device Designation; CE mark under EU MDR; US pivotal IDE trial ongoing
Economics	Terms undisclosed at announcement; no royalty layer
Date	Mon June 8, 2026

Royalty read
Structure	Medtech equity acquisition, undisclosed terms, no royalty mechanics
Read	The window's third corporate combination and a strategic pivot, not a royalty-relevant transaction

Treeline Biosciences / Standard BioTools: All-Stock Reverse Merger, ~$2.5B Treeline Equity Value (Mon June 8)

Treeline Biosciences (Stamford, CT; privately held oncology company) agreed to combine with Standard BioTools (Nasdaq: LAB) in an all-stock merger that takes Treeline public, with the combined company keeping the Treeline name and trading as TRLN (release).

The exchange ratio is set against an assumed Treeline equity value of ~$2.5B versus Standard BioTools at ~$460M, leaving pro forma ownership of roughly 84% Treeline and 16% Standard BioTools. The combined company expects over $900M in cash at closing, funding a runway into 2029. Pre-merger Standard BioTools holders receive a five-year contingent value right (capped at 76 million combined-company shares) paying net proceeds from the legacy Mass Cytometry and Microfluidics businesses plus up to $50M in earnout tied to Illumina's earlier SomaLogic acquisition. Closing targeted 2H 2026.

Term	Detail
Acquirer / public vehicle	Standard BioTools Inc. (Nasdaq: LAB), to be renamed Treeline Biosciences Holdings, Inc. (ticker TRLN)
Target / surviving identity	Treeline Biosciences (Stamford, CT; founded 2021 by CEO Josh Bilenker, ex-Loxo, and CSO Jeff Engelman, ex-Novartis NIBR; backers ARCH, OrbiMed, GV, KKR, Casdin, Access Industries)
Structure	All-stock reverse merger; tax-free; ~84% Treeline / ~16% Standard BioTools fully diluted; $16.1M termination fee; 180-day insider lock-ups
Valuation	~$2.5B Treeline equity value; ~$460M Standard BioTools; $900M+ combined cash; runway into 2029
CVR	Five-year term, capped at 76M shares; net proceeds from legacy Mass Cytometry and Microfluidics plus up to $50M Illumina / SomaLogic earnout
Pipeline	Phase 1 oncology: BCL6 degrader TLN-121, EZH2 inhibitor TLN-254, pan-KRAS inhibitor TLN-372; BCL-XL degrader TLN-499 clinic-bound later in 2026
Upstream royalty	TLN-254 (EZH2; SHR-2554) in-licensed from Jiangsu Hengrui (2023, ex-Greater China): $11M upfront, up to $45M development and up to $650M sales milestones, plus 10 to 12.5% royalties to Hengrui
Advisers	Centerview Partners (financial), Freshfields and Richards, Layton & Finger (legal), and UBS (financial, to the Special Committee) to Standard BioTools; Wedbush Securities (financial) and Fenwick & West (legal) to Treeline
Date	Mon June 8, 2026

Royalty read
Upstream licensor royalty	TLN-254 carries a 10 to 12.5% royalty to Hengrui on net sales, a live third-party obligation that travels with the asset and a stream Hengrui could monetise once sales begin
CVR	A royalty-adjacent contingent-payment instrument, here tied to legacy diagnostics asset sales and the Illumina / SomaLogic earnout rather than a drug royalty
Structure	A corporate combination and going-public transaction, not a royalty origination; the $900M+ cash is balance-sheet cash, not a new third-party raise
Caveat	Fundraising figures differ (~$1.1B per Fierce Biotech late 2025 vs ~$1.2B in the June 8 release); the Hengrui royalty band is from 2023 reporting and should be confirmed against the merger proxy

BioNTech / Founders: mRNA Carve-Out and Separation, Undisclosed Terms (Handelsblatt Mon June 8)

BioNTech (Nasdaq: BNTX; Mainz, Germany) and its founders Ugur Sahin and Ozlem Tureci have largely finalised the terms of their separation, first announced March 10, 2026, under which the pair will leave operational and board roles by end-2026 to start a new independent next-generation mRNA company (Handelsblatt).

Per Handelsblatt, BioNTech would transfer its early-stage CAR-T cell therapy portfolio and RiboMAB programme (mRNA-encoded antibodies) to the founders' new company, with roughly 300 mostly research staff expected to move. BioNTech retains the patents on its drug candidates, with the founders receiving a license to develop RiboMAB further and an option to return the technology later. The separation sits against a broader BioNTech restructuring (up to ~1,860 job cuts by end-2027).

Term	Detail
Parties	BioNTech SE (Nasdaq: BNTX; Mainz) and founders Ugur Sahin and Ozlem Tureci
Structure	Corporate carve-out plus governance transition; founders exit by end-2026; binding agreement targeted end of H1 2026
Transferred assets	Early-stage CAR-T portfolio and RiboMAB; ~300 mostly research employees
Retained by BioNTech	Patents on drug candidates; commercial and late-stage business, including the Pfizer / Comirnaty profit split and other commercial royalty streams; iNEST
Consideration to BioNTech	Minority stake plus milestones and royalties (arm's length per March 10 release); RiboMAB license-back option
Status	Asset valuation under negotiation; specifics from company circles, not yet confirmed by BioNTech
Date	Handelsblatt report Mon June 8, 2026; split announced March 10, 2026

Royalty read
In-scope stream	The inbound line back to BioNTech: a minority stake plus milestones and royalties from the new company, contributed on an arm's length basis
Structure	A rare case of a large-cap originating a fresh inbound royalty-and-milestone line through a corporate split, plus a RiboMAB license-back option preserving optionality
Status	Economics (rate, milestone schedule, stake size, patent valuation) not yet public; await the binding agreement targeted end of H1 2026
Out of scope	The marquee royalty and profit-share franchises (Pfizer / Comirnaty chief among them) stay in the commercial business retained by BioNTech

Magle Group: Bondholder Restructuring, Debt-for-Control Workout (Thu June 11)

Magle Chemoswed Holding AB (Nasdaq First North; Sweden; API, degradable starch microspheres, wound care and diagnostics, via subsidiaries Magle Chemoswed AB and Adroit Science AB) announced agreement in principle on the key principles of a restructuring with an ad hoc group of holders representing about 70% of its outstanding SEK 350M senior secured floating-rate bonds 2025/2028 (ISIN SE0025197403) (MarketScreener).

The terms point to a debt-for-control outcome, with bondholders set to convert into equity and potentially take control of the group. The update follows a stretched workout: an April written-procedure waiver of the maintenance tests conditional on raising at least SEK 100M of net proceeds by June 30, a ~SEK 40M rights issue, a 3% consent-fee set-off issue (~SEK 9.3M), and a bridge loan of up to SEK 60M from existing bondholders, all against the June 30 maturity of a Danske Bank facility. The associated written procedure runs to a June 22 voting deadline.

Term	Detail
Company	Magle Chemoswed Holding AB (Nasdaq First North; Sweden; subsidiaries Magle Chemoswed AB and Adroit Science AB)
Instrument	SEK 350M senior secured floating-rate bonds 2025/2028 (ISIN SE0025197403)
Counterparty	Ad hoc group holding ~70% of the bonds (~73.8% under the May bridge-loan agreement)
Structure	Agreement in principle on key restructuring terms; debt-for-equity conversion, bondholders may take control
Context	April maintenance-test waiver conditional on SEK 100M net proceeds by June 30; ~SEK 40M rights issue; ~SEK 9.3M consent-fee set-off; up to SEK 60M bondholder bridge loan; Danske Bank facility maturing June 30
Process	Written procedure with a June 22 voting deadline
Date	Thu June 11, 2026

Royalty read
Royalty layer	None; a distressed balance-sheet restructuring, not a royalty origination or monetisation
Read	A small-cap distressed debt-for-control workout. Of structural interest only as a worked example of senior secured bondholders converting to equity in a sub-scale pharma-chemistry issuer, not a tradable royalty stream

PharmaEssentia / FORUS Therapeutics: Canadian BESREMi Licensee Buy-In, US$36.5M (Closed Thu June 11; Agreed April 9)

PharmaEssentia Corporation (TWSE: 6446; Taipei and Burlington, MA) closed the acquisition of 100% of FORUS Therapeutics Inc. (Oakville, Ontario), its Canadian commercialisation licensee for BESREMi (ropeginterferon alfa-2b-njft) in polycythemia vera, in a transaction valued at US$36.5M (C$50M) (PharmaEssentia release). The acquisition was agreed April 9, 2026 and completed June 11, 2026; only the closing falls inside this window.

Under the October 31, 2024 exclusive Canada license, FORUS registered and commercialised BESREMi for PV (New Drug Submission to Health Canada July 2025, approval expected Q3 2026) and owed PharmaEssentia up to $107M in milestones plus double-digit percentage royalties on Canadian net sales. By buying FORUS outright, PharmaEssentia retires that downstream royalty and milestone obligation and brings Canadian regulatory, medical, and commercial capability in-house. FORUS's existing Karyopharm relationship (XPOVIO) travels with the team.

Term	Detail
Acquirer	PharmaEssentia Corporation (TWSE: 6446; Founder and CEO Ko-Chung Lin)
Target	FORUS Therapeutics Inc. (Oakville, Ontario; CEO Kevin Leshuk), PharmaEssentia's Canadian BESREMi licensee since October 2024
Asset	BESREMi (ropeginterferon alfa-2b-njft) in polycythemia vera; essential thrombocythemia submission in preparation
Structure	Acquisition of 100% of FORUS; US$36.5M (C$50M)
Retired economics	The October 2024 Canada license carried up to $107M in milestones plus double-digit percentage royalties payable by FORUS to PharmaEssentia on Canadian net sales
Timing	Agreed April 9, 2026; closed June 11, 2026

Royalty read
Structure	Royalty-retiring acquisition: PharmaEssentia buys in its own licensee, collapsing a downstream royalty into wholly owned commercial economics
Tradable element	None created. The transaction removes a third-party royalty rather than originating one, the inverse of an aggregator purchase
Read	A small but instructive in-window print for royalty tracking: an originator electing to retire a royalty by acquiring the payer, the opposite of monetisation. Logged as M&A, royalty-eliminating, not royalty paper

---

BD Origination and Licensing

Seven royalty-bearing items anchor this section. Roche / Nurix bexobrutideg ($700M upfront, up to $2.3B) is the window's lead royalty-bearing event. Orionis / Novartis ($40M upfront, up to $1.4B) is a platform-discovery collaboration carrying tiered royalties to a privately held originator. Laekna / Vasque Bio pairs a tiered royalty with a high-teens equity option.

AlzeCure / Lilly and Engitix / GSK are European originator out-licences. Medexus / ExCellThera originates a small regional Canadian commercial royalty, and AmMax / Lonza marks a Basel CDMO platform-royalty model.

Roche / Nurix Therapeutics: Bexobrutideg (NX-5948), Up to $2.3B (Mon June 8)

Nurix Therapeutics (Nasdaq: NRIX; San Francisco; originator and licensor) entered an exclusive licensing and collaboration agreement with Roche (SIX: RO, ROP; OTCQX: RHHBY) to co-develop and co-commercialise bexobrutideg (NX-5948), an oral, brain-penetrant BTK degrader, across B-cell malignancies, immunology, and neurology (Roche release).

Nurix receives a $700M upfront and is eligible for milestones to a total of up to $2.3B. Development costs split 40% Nurix / 60% Roche. In the US the two co-commercialise and split profits and losses equally; outside the US Roche commercialises and Nurix receives low- to high-teens tiered royalties. Phase 3 initiation is planned for summer 2026 in second-line CLL.

Term	Detail
Licensor / originator	Nurix Therapeutics, Inc. (Nasdaq: NRIX; San Francisco; CEO Arthur T. Sands)
Licensee / partner	Roche (SIX: RO, ROP; OTCQX: RHHBY; Levi Garraway, CMO and Head of Global Product Development)
Asset	Bexobrutideg (NX-5948): oral, brain-penetrant BTK degrader; eliminates both the kinase and scaffolding functions of BTK rather than inhibiting the active site
Lead indication / stage	r/r B-cell malignancies; Phase 3 planned summer 2026 in 2L CLL; expansion into immunology (CSU) and neurology (MS)
Geography	Global; US co-commercialisation by both parties, ex-US by Roche
Economics	$700M upfront plus milestones (up to $2.3B); 60/40 Roche/Nurix development cost share; 50/50 US profit-and-loss split; low- to high-teens tiered royalties to Nurix on ex-US net sales
Condition	Subject to HSR clearance; closing targeted Q3 2026
Advisers	Goodwin Procter (legal) to Nurix; Roche advisers not disclosed
Date	Mon June 8, 2026

Royalty read
Tradable instrument	Low- to high-teens tiered royalty to Nurix on Roche's ex-US net sales
Stacked on	$700M upfront and a milestone ladder within the $2.3B ceiling
Non-royalty economics	50/50 US profit-and-loss split (co-promote economics, not a royalty); Nurix funds 40% of development
Read	A US-origin royalty line in the making, accruing to a clinical-stage developer that also retains a 50% US economic interest; the disclosed band is wider and more concrete than the single-digit and undisclosed W23 Asia-outbound rates
Caveat	Lead value gated on the summer 2026 2L CLL Phase 3; CSU and MS are earlier; the 40% cost share offsets near-term cash

Orionis Biosciences / Novartis: Molecular Glue Discovery Collaboration, $40M Upfront, Up to $1.4B (Tue June 10)

Orionis Biosciences (Boston and Ghent, Belgium; HQ Waltham, MA; privately held, clinical-stage) entered a renewed and expanded multi-year collaboration with Novartis (NYSE: NVS; SIX: NOVN) to discover and design molecular glue drugs for challenging targets across multiple disease areas, deploying Orionis's Allo-Glue platform and AI discovery engine (Business Wire).

Orionis receives a $40M upfront and is eligible for research, development, and commercial milestones of up to $1.4B, plus tiered royalties on net sales of collaboration products. The deal renews and expands a 2020 four-year discovery pact.

Term	Detail
Licensor / originator	Orionis Biosciences (Boston / Ghent; HQ Waltham, MA; privately held, clinical-stage; CEO Niko Kley)
Licensee / partner	Novartis (NYSE: NVS; SIX: NOVN; John Tallarico, Head of Discovery Sciences)
Structure	Multi-year discovery and development collaboration; renewal and expansion of the 2020 pact; Allo-Glue platform plus AI discovery engine
Modality / focus	Small-molecule molecular glues modulating targets via induced proximity; oncology, immunology, and more
Economics	$40M upfront; up to $1.4B in milestones; tiered royalties to Orionis on net sales of collaboration products
Date	Tue June 10, 2026

Royalty read
Tradable instrument	Tiered royalty to Orionis on Novartis's net sales of collaboration products
Stacked on	$40M upfront and a milestone ladder to $1.4B
Structure	Platform-discovery collaboration, so the royalty is portfolio-wide and contingent on programmes Novartis advances; a long-dated, multi-programme stream
Read	A privately held, clinical-stage originator retaining a royalty against a large-cap on a validated, repeat-partner platform; a forward monetisation candidate once programmes advance
Caveat	No collaboration product is yet in the clinic from this pact; the rate band is not specified; $1.4B is a ceiling, not committed value

Laekna / Vasque Bio: LAE118 Ex-Greater-China Out-Licence, Up to $527M Plus Equity (Tue June 9)

Laekna, Inc. (HKEX: 02105; Shanghai) entered an exclusive licensing agreement granting Vasque Bio, Inc. (US; clinical-stage, rare-disease-focused; backed by The Column Group and F-Prime) worldwide rights excluding Greater China to develop, manufacture, and commercialise LAE118, an internally discovered PI3K-alpha pan-mutant-selective inhibitor (Laekna disclosure via Minichart).

Laekna receives a $10M non-refundable upfront, is eligible for up to $517M in combined milestones (up to $527M total), and retains tiered royalties ranging from single-digit to double-digit percentages on net sales. In addition, Laekna holds the right to acquire, at no extra cost, up to a high-teens percentage of Vasque's common stock, or cash in lieu. A structurally uncommon clause further entitles Laekna to up to 50% of the value of any qualifying strategic transaction (an acquisition or sublicence of LAE118) that Vasque enters, guarding the originator against an early, cheap exit before milestones are earned. LAE118 has cleared IND review with the US FDA and China's NMPA.

Term	Detail
Licensor / originator	Laekna, Inc. (HKEX: 02105; Shanghai; retains Greater China rights and an oncology focus)
Licensee / partner	Vasque Bio, Inc. (US; clinical-stage, rare-disease focus; The Column Group and F-Prime backed; ex-Greater-China rights)
Asset	LAE118: allosteric PI3K-alpha pan-mutant-selective inhibitor; IND-cleared in the US and China; PIK3CA-mutant solid tumours and overgrowth-spectrum disorders
Geography	Worldwide excluding Mainland China, Hong Kong, Macau, and Taiwan
Economics	$10M upfront; up to $517M milestones (up to $527M total); tiered single- to double-digit royalties to Laekna
Equity	Laekna's right to acquire up to a high-teens percentage of Vasque common stock at no extra cost, or cash in lieu
Transaction upside	Up to 50% of the value of any qualifying strategic transaction (acquisition or sublicence of LAE118) that Vasque enters; an uncommon anti-flip clause
Date	Tue June 9, 2026

Royalty read
Tradable instrument 1	Tiered single- to double-digit royalty to Laekna on Vasque's ex-Greater-China net sales
Stacked on	$10M upfront and an up-to-$517M milestone ladder
Tradable instrument 2	An equity option: up to a high-teens stake in the licensee at no cost, converting part of the downstream economics into direct exposure to a Vasque exit
Tradable instrument 3	A contingent claim on up to 50% of the value of any qualifying Vasque strategic transaction (acquisition or sublicence) on LAE118, an anti-flip provision that captures exit value before milestones are earned
Read	A royalty-plus-equity-plus-transaction-upside hybrid distinct from the royalty-only out-licences (AlzeCure, Engitix); China-outbound, sub-scale originator band; extends the W23 Asia-outbound theme; forward monetisation candidate
Caveat	Early clinical-stage and milestone-weighted; the field is well-capitalised (Novartis / Synnovation up to $3B, March 2026); terms from HKEX disclosure and secondary reporting

AlzeCure Pharma / Eli Lilly: ACD680 Gamma-Secretase Modulator, >$1B Excluding Royalties (Tue June 9)

AlzeCure Pharma (Nasdaq First North Growth Market Stockholm: ACURE; Huddinge, Sweden) entered a collaboration and out-licensing agreement granting Eli Lilly (NYSE: LLY) global rights to ACD680, a gamma-secretase modulator from AlzeCure's Alzstatin platform for Alzheimer's disease (BioStock). AlzeCure receives a $10M upfront and is eligible for milestones to a total exceeding $1B excluding royalties, plus mid-single-digit royalties. AlzeCure shares rose more than 300% on the announcement.

ACD680 reduces production of the harmful Abeta42 peptide while increasing shorter, non-aggregating Abeta species. The transaction is subject to Swedish FDI screening clearance.

Term	Detail
Licensor / originator	AlzeCure Pharma AB (Stockholm: ACURE; Huddinge, Sweden; CEO Martin Jonsson)
Licensee / partner	Eli Lilly and Company (NYSE: LLY)
Asset	ACD680: gamma-secretase modulator (Alzstatin platform); shifts amyloid processing from Abeta42 toward shorter non-aggregating species
Indication / stage	Alzheimer's disease; early-stage, with potential preventive positioning
Geography	Global
Economics	$10M upfront; milestones to a total exceeding $1B excluding royalties; mid-single-digit royalties to AlzeCure
Condition	Subject to Swedish foreign direct investment screening clearance
Date	Tue June 9, 2026

Royalty read
Tradable instrument	Mid-single-digit royalty to AlzeCure on Lilly's global net sales
Stacked on	A modest $10M upfront and a milestone ladder carrying the headline past $1B
Structure	A clean single-asset originator royalty: no cost share or co-promote, so the entire downstream interest sits in the royalty and milestones
Read	The cut's cleanest CFC-shaped origination: a sub-scale European originator to a US large-cap, retaining a running royalty; a forward monetisation candidate once de-risked
Caveat	Early-stage in one of the hardest CNS indications; value is milestone-dominated and the royalty is long-dated; the Swedish FDI gate is a genuine closing condition

Medexus / ExCellThera and Cordex: UM171 Cell Therapy Canadian License and Supply, $2M Upfront Plus Royalties (Tue June 9)

Medexus Pharmaceuticals (TSX: MDP; OTCQX: MEDXF; Toronto and Chicago) secured exclusive Canadian commercialisation rights to UM171 Cell Therapy (Zemcelpro / dorocubicel) under license and supply agreements with ExCellThera Inc. (Montreal) and its wholly owned subsidiary Cordex Biologics (Medexus release).

Medexus pays a $2M upfront, will make quarterly royalty payments to ExCellThera on net sales, and owes one-time milestones. Cordex manages the planned pivotal Phase 3 trial and supplies product on a cost-plus basis. UM171 is conditionally approved in the EU as Zemcelpro; the brand has not yet been reviewed by Health Canada.

Term	Detail
Licensee	Medexus Pharmaceuticals Inc. (TSX: MDP; OTCQX: MEDXF; Toronto / Chicago; exclusive Canadian rights)
Licensor / originator	ExCellThera Inc. (Montreal) and Cordex Biologics (wholly owned subsidiary; manages Phase 3 and supply)
Asset	UM171 Cell Therapy (Zemcelpro / dorocubicel): expanded allogeneic haematopoietic stem-cell therapy; conditionally EU-approved; allo-HSCT in haematological malignancies
Geography	Canada (subject to Health Canada review)
Economics	$2M upfront; quarterly royalties to ExCellThera on Canadian net sales; one-time milestones; Cordex supplies on a cost-plus basis
Date	Tue June 9, 2026

Royalty read
Tradable instrument	Quarterly royalty to ExCellThera on Medexus's Canadian net sales
Stacked on	A $2M upfront and one-time milestones
Structure	A small single-territory commercial royalty on a conditionally-EU-approved cell therapy, accruing to the Canadian originator; the cost-plus supply keeps manufacturing economics with Cordex
Read	Closer to a near-term cash-bearing stream than the discovery-stage out-licences, though the Canada-only scope and Health Canada gate cap its size
Caveat	Royalty rate and milestone amounts beyond the $2M upfront were not disclosed; launch contingent on Health Canada review and payer engagement

Engitix / GSK: Liver Fibrosis Regression Target Collaboration and Option, Up to GBP 44.5M Upfront and Near-Term (Mon June 8)

Engitix Ltd. (London; privately held) entered a strategic research collaboration and option agreement with GSK (LSE / NYSE: GSK) to identify and validate first-in-class targets driving liver fibrosis regression, pairing Engitix's human extracellular-matrix (ECM) platform and multi-omics datasets with GSK's development capabilities (GlobeNewswire).

Engitix is eligible for up to GBP 44.5M in upfront and near-term payments, up to GBP 118M per target in downstream milestones, and tiered low-single-digit royalties on future product sales. GSK holds the option to license the validated targets and would lead development.

Term	Detail
Licensor / originator	Engitix Ltd. (London; privately held; ECM-driven drug discovery)
Licensee / partner	GSK (LSE / NYSE: GSK; Kaivan Khavandi, SVP, R&D)
Structure	Research collaboration and option agreement; GSK option to license targets, datasets, and assays; GSK leads development
Platform / focus	Human ECM platform and multi-omics datasets; liver fibrosis regression (resolution) rather than progression
Economics	Up to GBP 44.5M upfront and near-term; up to GBP 118M per target in milestones; tiered low-single-digit royalties to Engitix
Date	Mon June 8, 2026

Royalty read
Tradable instrument	Tiered low-single-digit royalty to Engitix on net sales of any product GSK takes forward
Stacked on	Per-target milestone ladders (up to GBP 118M each) and the GBP 44.5M upfront and near-term band
Structure	The earliest-stage royalty in the cut: platform- and target-discovery driven, contingent on GSK exercising its option and carrying targets through development; a long-dated, multi-step option
Read	An origination watch item; the trigger to elevate is GSK exercising its option on a defined target
Caveat	Private originator, several validated-target and development steps from product sales; the GBP 118M figure is per target, not aggregate

AmMax Bio / Lonza: ADC Linker-Payload Platform License, Terms Undisclosed (Tue June 9)

AmMax Bio, Inc. (Redwood City, CA; private, clinical-stage) entered a non-exclusive licensing agreement with Lonza (SIX: LONN; Basel) for access to Lonza's GlycoConnect conjugation, HydraSpace spacer, and exatecan-based SYNtecan linker-payload technologies, to develop AMB-104, an ADC for venetoclax / azacitidine-resistant AML (Contract Pharma).

Financial terms were not disclosed. AmMax plans an IND in early 2027. The structure mirrors Lonza's Stipple Bio ADC platform license one week earlier (June 4), which disclosed upfront, milestone, and net-sales royalty terms to Lonza.

Term	Detail
Licensee	AmMax Bio, Inc. (Redwood City, CA; private, clinical-stage; Chairman and CEO Larry Hsu)
Licensor / originator	Lonza (SIX: LONN; Basel; CDMO; conjugation and linker-payload platform owner)
Asset	AMB-104: ADC combining AmMax's monoclonal antibody with Lonza's linker-payload technologies; venetoclax / azacitidine-resistant AML; IND targeted early 2027
Structure	Non-exclusive platform license (GlycoConnect, HydraSpace, SYNtecan); Lonza manufactures proprietary-technology components
Economics	Terms undisclosed; Lonza's June 4 Stipple Bio license disclosed upfront, milestones, and net-sales royalties to Lonza
Date	Tue June 9, 2026

Royalty read
Tradable instrument	A net-sales royalty to Lonza, inferred from the Stipple Bio comparator (not disclosed for AMB-104)
Model	Lonza's ADC platform-licensing originates a CDMO platform royalty: a stream on the licensee's product sales in exchange for access to its conjugation and linker-payload IP
Read	A Basel-origin platform royalty held by a large listed CDMO; two licenses in one week (Stipple June 4, AmMax June 9) point to a repeatable, poolable royalty book
Caveat	AmMax terms undisclosed, the asset preclinical (IND 2027); the royalty is inferred from the comparator and Lonza's stated model, not from disclosed AMB-104 terms

---

Structured Finance and Non-Dilutive Debt

Two structured-finance prints in the window. The Pharmakon Advisors / Idorsia senior secured term loan of up to CHF 250M is debt rather than a royalty monetisation, the one in-window deal from a house on the structured-finance watchlist and a Swiss commercial-stage borrower. The Beren Therapeutics / Hercules Capital financing of about $300M is the more royalty-relevant of the two: alongside $135M of equity, the Hercules tranche pairs senior secured debt with a $55M royalty-financing sleeve on a pre-commercial rare-disease asset, the window's only explicit royalty layer.

Pharmakon Advisors (BioPharma Credit) / Idorsia: Senior Secured Term Loan, Up to CHF 250M (Tue June 9)

Idorsia Ltd (SIX: IDIA; Allschwil, Switzerland; commercial-stage, lead product QUVIVIQ / daridorexant) entered a senior secured term loan of up to CHF 250M with funds managed by Pharmakon Advisors, LP, the manager of the BioPharma Credit funds (Idorsia release).

The first tranche of CHF 150M funds at closing to fully refinance the existing New Money Facility (CHF 105M drawn, due May 2027), extending runway into 2028. The loan carries a 5-year maturity at a fixed 7% rate.

Term	Detail
Lender	Pharmakon Advisors, LP (manager of the BioPharma Credit funds; ~$13B committed across 77 investments since 2009)
Borrower	Idorsia Ltd (SIX: IDIA; Allschwil, Switzerland; Chairman and interim CEO Jean-Paul Clozel)
Instrument	Senior secured term loan, up to CHF 250M; first tranche CHF 150M at closing; further tranches subject to conditions
Pricing / tenor	Fixed 7% interest rate; 5-year maturity
Use of proceeds	Refinance the existing New Money Facility; eliminate near-term maturities; extend runway into 2028
Date	Tue June 9, 2026

Royalty read
Instrument	Non-dilutive senior secured debt against Idorsia's commercial base; not a royalty purchase or synthetic royalty
Why logged	Pharmakon (BioPharma Credit) is on the structured-finance watchlist; this is the one such print in the window and a live pricing data point (fixed 7%, 5-year) for senior secured life-sciences debt against a single commercial franchise
Read	A Swiss commercial-stage borrower with both a debt and a royalty-monetisation path took the debt route
Caveat	This is the credit product, not royalty paper, and should not be counted as royalty originated or traded; only CHF 150M of the CHF 250M is funded at closing

Beren Therapeutics / Hercules Capital: $300M Equity and Royalty-Backed Financing for Adrabetadex (Wed June 10)

Beren Therapeutics P.B.C. (Thousand Oaks, CA; founder-led, CEO Jason Camm; parent of Mandos LLC) secured about $300M in combined financing to fund commercial readiness for adrabetadex, its cyclodextrin therapy for infantile-onset Niemann-Pick disease type C (I-NPC), ahead of a November 17, 2026 PDUFA target action date (Business Wire).

The package splits into a $135M equity round (Wellington Partners, JIC Venture Growth Investments, Founders Fund, Narya Capital, Eisai Co., Ltd., and other institutional investors) and up to $165M of non-dilutive capital from Hercules Capital (NYSE: HTGC), structured as senior secured debt plus $55M of royalty financing. Adrabetadex (a 2-hydroxypropyl-beta-cyclodextrin isomer mixture) holds FDA Breakthrough Therapy designation and is under Priority Review; the PDUFA date was extended three months after an FDA major-amendment request.

Term	Detail
Originator / borrower	Beren Therapeutics P.B.C. (Thousand Oaks, CA; CEO Jason Camm; parent of Mandos LLC)
Capital providers	Equity: Wellington Partners, JIC VGI, Founders Fund, Narya Capital, Eisai, others. Non-dilutive: Hercules Capital (NYSE: HTGC)
Structure	$135M equity plus up to $165M from Hercules (senior secured debt and $55M royalty financing); ~$300M total
Asset	Adrabetadex: 2-hydroxypropyl-beta-cyclodextrin isomer mixture for I-NPC
Regulatory status	FDA Breakthrough Therapy; NDA under Priority Review; PDUFA Nov 17, 2026 (extended three months after a major amendment)
Market	I-NPC is a rare, rapidly fatal pediatric neurodegenerative disease; two entrants are already approved, Zevra's Miplyffa (arimoclomol) and IntraBio's Aqneursa (levacetylleucine), with Miplyffa's exclusivity recently extended to November 2041
Use of proceeds	Commercial readiness, patient access, and family-support programmes
Date	Wed June 10, 2026

Royalty read
Tradable element	The $55M Hercules royalty-financing sleeve is a pre-approval royalty layer on a single rare-disease asset, a synthetic-royalty-style structure on an unapproved drug
Why logged	A credit-and-royalty house funding pre-commercial launch readiness is exactly the structured-finance pattern on the watchlist; the royalty sleeve, not the equity or the senior debt, is the royalty-relevant piece
Read	A forward origination rather than a present aggregator purchase, but a clean example of royalty financing sized to a sub-scale orphan asset, in CFC's defensible band
Caveat	Approval is not yet secured (Nov 17 PDUFA, with a prior major-amendment delay); the royalty layer is contingent on launch, and the I-NPC market already has two approved entrants

---

Financings

Five raises. The Parabilis Medicines IPO ($670M, ~$745M with the Regeneron placement) is the largest venture-backed biotech IPO on record. SonoThera's $125M Series B is the window's largest venture round, ahead of the City Therapeutics $99.5M Series B.

Samsung Electronics' $175M investment in Element Biosciences is a tools financing. The smaller Cantargia rights issue plus a Fenja Capital loan is a dilutive raise with a venture-debt sleeve.

Parabilis Medicines: Record $670M IPO Plus $75M Regeneron Private Placement (Priced Tue June 9)

Parabilis Medicines, Inc. (Nasdaq: PBLS; Cambridge, MA; founded 2015 as Fog Pharmaceuticals; CEO Mathai Mammen, ex-J&J global R&D head) priced an upsized IPO of 33.5M shares at $20, above the $17 to $19 range after two same-day upsizings, for $670M gross, with a 5.025M-share overallotment that could lift the total to ~$770M (pricing release).

In a concurrent private placement, Regeneron agreed to buy ~4.17M shares at $18, ~$75M, in connection with a separate research collaboration, bringing total proceeds to ~$745M. The largest IPO in venture-backed biotech history (above Kailera's $625M and Moderna's $604M). Parabilis is building the Helicon peptide platform for undruggable targets; lead asset zolucatide is a Wnt / beta-catenin inhibitor in desmoid tumours.

Term	Detail
Issuer	Parabilis Medicines, Inc. (Nasdaq: PBLS; Cambridge, MA; CEO Mathai Mammen)
Structure	Upsized IPO: 33.5M shares at $20 (above range); 5.025M-share overallotment; concurrent Regeneron private placement of ~4.17M shares at $18
Proceeds	~$670M IPO gross (up to ~$770M with overallotment); ~$75M Regeneron placement; ~$745M total
Platform / lead	Helicon peptide platform; lead zolucatide (Wnt / beta-catenin) in desmoid tumours; ERG, AR, beta-catenin degraders
Underwriters	Leerink Partners (lead), with BofA Securities, Evercore and Guggenheim Securities as joint bookrunning representatives
Date	Priced Tue June 9; trading began Wed June 10, 2026

Royalty read
Instrument	A primary equity raise, not a royalty origination; Parabilis sells its own stock
Royalty-adjacent	The Regeneron private placement is tied to a separate, undisclosed research collaboration; if it carries milestones or royalties, that would be the tradable layer, but nothing is public yet
Read	A record biotech IPO and a marker of a strongly open equity window, the funding alternative against which originators weigh non-dilutive royalty monetisation

SonoThera: $125M Series B (Wed June 10)

SonoThera, Inc. (South San Francisco) closed an oversubscribed $125M Series B to take its ultrasound-mediated nonviral genetic-medicine platform (RIPPLE delivery plus PORE payload engineering) into the clinic, with lead programmes in DMD and ADPKD and a Phase 1 targeted for 2027 (SonoThera release).

The round was led by Vida Ventures, with ARK Invest, CureDuchenne Ventures, Leaps by Bayer, Otsuka, SymBiosis, UCB Ventures, and Vivo Capital joining existing backers ARCH, Alexandria, Duquesne Family Office, Illumina Ventures, JJDC, Medical Excellence Capital, RA Capital, and Vertex Ventures HC.

Term	Detail
Company	SonoThera, Inc. (South San Francisco; nonviral genetic medicine)
Round	Oversubscribed $125M Series B; led by Vida Ventures
Platform / lead	RIPPLE (ultrasound-mediated delivery) plus PORE (payload engineering); DMD and ADPKD; Phase 1 targeted 2027
Date	Wed June 10, 2026

Royalty read
Instrument	A clean equity raise with no royalty origination
Read	The window's largest venture round, above City's $99.5M, and a marker of conviction in nonviral, redosable delivery as an alternative to viral vectors
Watch	A platform and pipeline to track for any future inbound or outbound royalty structure

City Therapeutics: $99.5M Series B (Mon June 8)

Cambridge, MA-based City Therapeutics closed a $99.5M Series B co-led by Viking Global Investors and Sofinnova Investments, joined by Casdin Capital and NYBC Ventures and existing backers including ARCH, Fidelity, Invus, Slate Path, Rock Springs, and Regeneron Ventures (GEN). The raise takes total funding past $230M since the 2024 launch.

City is building a next-generation RNAi platform around cityRNAs, short cleavage-inducing tiny RNAs that activate Argonaute-3 (AGO3) to reach extrahepatic tissues. Lead program CITY-FXI (Factor XI) is in Phase 1. The company is Alnylam-pedigreed, chaired by Alnylam founding CEO John Maraganore.

Term	Detail
Company	City Therapeutics, Inc. (Cambridge, MA; chair John Maraganore, CEO Andy Orth)
Round	$99.5M Series B (total funding past $230M since 2024 launch)
Investors	Viking Global, Sofinnova (co-leads); Casdin, NYBC Ventures (new); ARCH, Fidelity, Invus, Slate Path, Rock Springs, Regeneron Ventures (existing)
Platform	cityRNAs: cleavage-inducing tiny RNAs activating Argonaute-3 (AGO3) for extrahepatic delivery (CNS, eye, muscle, fat, lung)
Lead programs	CITY-FXI (Factor XI; Phase 1); CITY-RBP4 (Stargardt disease; clinic-bound 2026); third program by year-end
Date	Mon June 8, 2026

Royalty read
Inbound royalties	City holds (rather than owes) tiered royalty rights under its Biogen (up to ~$1B milestones plus royalties) and Bausch + Lomb (up to $485M plus royalties) out-licenses
Academic IP	The platform rests on Ohio State research (Nakanishi AGO3 lab, federally funded); under Bayh-Dole an upstream university license would normally apply, but none is publicly disclosed
Read	A clean equity raise, no upstream royalty monetisation today
Watch	Any future S-1 disclosure of the Ohio State upstream terms, and any monetisation of City's inbound Biogen and Bausch + Lomb royalty rights

Element Biosciences: $175M Series E (Samsung Electronics) (Tue June 9)

Element Biosciences raised a Series E with Samsung Electronics investing $175M in the DNA-sequencing and life-science-tools company (Reuters).

Royalty read
Instrument	A tools and instrumentation financing, not a therapeutic royalty event; outside the royalty origination universe
Read	A strategic corporate investment (a large electronics group taking a sequencing-tools stake), with no tradable drug royalty layer

Cantargia: ~SEK 124M Rights Issue plus up to SEK 75M Fenja Capital Loan (Subscription June 8 to 22)

Cantargia AB (Nasdaq Stockholm: CANTA; Lund, Sweden) launched a rights issue of approximately SEK 124M and, in parallel, a loan of up to SEK 75M with Fenja Capital, for combined gross proceeds of up to ~SEK 199M (BioStock). The issue is ~60% covered by commitments (DNB Bank guaranteeing SEK 72.6M); subscription runs June 8 to 22 at SEK 2.25 per share.

Cantargia develops antibody therapeutics against IL1RAP. Proceeds fund a Phase Ib combining nadunolimab with a RAS inhibitor (daraxonrasib) in pancreatic cancer, plus a haematology programme in MDS and AML.

Term	Detail
Company	Cantargia AB (Nasdaq Stockholm: CANTA; Lund, Sweden; CEO Hilde Steineger)
Raise	~SEK 124M rights issue plus up to SEK 75M Fenja Capital loan; up to ~SEK 199M gross combined
Terms	Subscription June 8 to 22; SEK 2.25 per share; ~60% covered by commitments (DNB Bank guaranteeing SEK 72.6M)
Lead asset	Nadunolimab (anti-IL1RAP); Phase Ib with daraxonrasib in PDAC; haematology programme in MDS / AML; bispecific CAN14
Date	Subscription opened Mon June 8, 2026

Royalty read
Royalty layer	None; a dilutive equity raise with a venture-debt sleeve
Read	The window's smaller raise and a read on tight Nordic small-cap oncology funding (a guaranteed, deeply discounted rights issue paired with venture debt)
Cross-reference	Pairs nadunolimab with daraxonrasib, the same pan-RAS asset underpinning Royalty Pharma's synthetic royalty (second $250M tranche activated April 13); daraxonrasib is becoming a backbone others build around, relevant to the durability of the royalty RPRX bought into

Circio Holding: ~NOK 300M Warrant Exercise and Underwritten Private Placement (Tue June 9)

Circio Holding ASA (OSE: CRNA; Oslo; CEO Erik Wiklund) completed its warrant-exercise programme plus a related underwritten private placement, securing about NOK 300M in gross proceeds and taking total H1 2026 fundraising to approximately NOK 620M (USD ~65M) (Circio release).

Of the 67,680,945 warrants issued with the February rights issue, 25,781,827 were exercised at NOK 8.2508 per share (about a 38% exercise rate, NOK 213M from more than 400 subscribers); the remaining ~NOK 87M was covered by the underwriting commitment announced May 26. Proceeds fund the circVec circular-RNA gene-expression platform and advance a lead gene-therapy programme to IND-filing and clinical proof of concept, with runway stated to the end of 2030.

Term	Detail
Company	Circio Holding ASA (OSE: CRNA; Oslo, Norway; CEO Erik Wiklund)
Raise	~NOK 300M gross (NOK 213M from warrant exercises at NOK 8.2508 per share; ~NOK 87M from underwriting); H1 2026 total ~NOK 620M (USD ~65M)
Use of proceeds	circVec circular-RNA platform; advance a lead gene-therapy programme to IND-filing and clinical proof of concept; runway to end-2030
Pipeline catalysts	In-vivo CAR T-cell delivery data (Q2), AAV-circVec wet-AMD model efficacy (Q2/Q3), CNS proof of concept from a big-pharma collaboration (Q3/Q4), heart-disease model efficacy (Q4)
Date	Tue June 9, 2026

Royalty read
Royalty layer	None; a clean dilutive equity print (warrant exercise plus underwritten placement)
Read	A Nordic platform raise that removes funding as the constraint and shifts the variable to 2026 preclinical readouts; a watch-list name for future platform-royalty potential if circVec out-licenses, but no royalty origination today

VERAXA Biotech / Voyager Acquisition Corp: Nasdaq Debut via De-SPAC (Closing June 10, Trading June 11)

VERAXA Biotech AG (Heidelberg and Zurich) completed its business combination with Voyager Acquisition Corp (Nasdaq: VACH), a SPAC sponsored by Cantor Fitzgerald, Voyager Acquisition Sponsor Holdco, and Odeon Capital Group, and began trading June 11, 2026 as VRXA (warrants VRXAW) (VERAXA release). VERAXA develops bispecific T-cell engagers and ADCs on its BiTAC platform.

The business combination agreement dates to April 22, 2025. The supporting financings, a $27.5M senior secured note (issued at 87.5% of par for ~$24.2M net) and a $50M share purchase agreement with Lincoln Park Capital, were signed May 27 and announced May 28, 2026. The only in-window event is the closing and listing, so the transaction is logged but not summed into this window's originated capital.

Royalty read
Structure	De-SPAC listing with a senior secured note and an equity line; no royalty or revenue-share component
Read	A going-public completion with pre-arranged, pre-window financing. No royalty content; tracked as a listing event only

Edesa Biotech: ~$3.5M Private Placement (Wed June 10, Announced June 11)

Edesa Biotech, Inc. (Nasdaq: EDSA; Markham, Ontario) agreed to sell 729,241 common shares in a private placement at $4.69 per share to outside investors and $5.21 per share to its CEO, for gross proceeds of about $3.5M, with no underwriter or placement agent; closing expected about June 15, 2026 (Edesa 8-K). Proceeds fund the paridiprubart vitiligo programme and working capital.

Royalty read
Structure	Small registered equity placement; no royalty or revenue-share component
Read	A micro-cap financing logged for completeness; no royalty content

---

Funds and Capital Formation

One in-window event, a medtech venture-fund first close. No dedicated healthcare royalty or credit fund closed in the window (the most recent comparables, OrbiMed Royalty & Credit V at $1.86B and Blackstone Life Sciences VI at $6.3B, predate it).

Star51 Capital: Inaugural Medtech and AI Venture Fund, First Close (Thu June 11)

Star51 Capital (New York) announced the first close of its inaugural fund, an operator-led venture vehicle positioned at the convergence of medtech and AI and described as an "ecosystem fund" bridging innovation and acquisition (PR Newswire).

The first close was led by Abbott and Mayo Clinic, with participation from senior medtech executives, physicians, and life-science professionals alongside the fund's general and operating partners, who committed their own capital as LPs. Star51 targets early and growth-stage companies across interventional therapies, diagnostics, monitoring, and the digitalization of healthcare, sourcing from the US, Europe, and the Middle East, and runs a proprietary internal AI platform, StarVision. The fund's target size and first-close amount were not disclosed.

Term	Detail
Manager	Star51 Capital (New York; operator-led medtech and AI venture platform)
Event	First close of the inaugural fund; size undisclosed
Anchor LPs	Abbott and Mayo Clinic, plus medtech-operator, physician, and life-science LPs and the GP and operating partners
Leadership	Founding Managing Partners Adam Rosenwach (ex-Coridea, Deerfield Catalyst) and Tal Wenderow (founder of Corindus Vascular Robotics, sold to Siemens Healthineers for $1.1B); Operating Partners Raymond W. Cohen, Scott Pantel (LSI), Joe Mullings (The Mullings Group)
Strategy	Early and growth-stage interventional therapies, diagnostics, monitoring, healthcare digitalization; US, Europe, Middle East
Date	Thu June 11, 2026

Royalty read
Royalty layer	None; a GP-level fund close, not a company transaction or royalty origination
Why logged	Tracked as LP-landscape intelligence: a new, dedicated pool of medtech and device capital with strategic (Abbott) and provider (Mayo Clinic) anchors, in CFC's device scope on the supply side
Read	Device and medtech venture remains fundable with the right operator and strategic anchors even in a selective market; a name to watch as a future originator of device-royalty and revenue-interest opportunities rather than a deal this window

---

Survodutide and Elecoglipron Royalty Re-Rates

The American Diabetes Association Scientific Sessions (June 5 to 8, New Orleans) produced a dense run of diabetes and obesity data. Two readouts carry a tradable third-party royalty. Most marquee obesity prints (Lilly retatrutide, Pfizer berobenatide, Roche petrelintide) landed June 5 to 6, just ahead of the window; survodutide (June 7) and the AstraZeneca / Eccogene elecoglipron Phase 2b presentation are the in-window events.

Boehringer Ingelheim / Zealand Pharma: Survodutide SYNCHRONIZE-1 and SYNCHRONIZE-MASLD Phase 3 (Sun June 7)

Boehringer Ingelheim (privately held; Ingelheim, Germany) and Zealand Pharma (Nasdaq Copenhagen: ZEAL) presented Phase 3 data for survodutide (BI 456906), a glucagon receptor and GLP-1 receptor dual agonist, at ADA 2026, with simultaneous publication in NEJM (SYNCHRONIZE-1, obesity) and Nature Medicine (SYNCHRONIZE-MASLD) (pharmaphorum). SYNCHRONIZE-1 (725 adults) showed up to a 16.6% average weight loss at 76 weeks versus 3.2% on placebo; SYNCHRONIZE-MASLD met its liver endpoints.

Term	Detail
Sponsor / developer	Boehringer Ingelheim (Ingelheim, Germany; leads development and commercialisation)
Originator / royalty holder	Zealand Pharma (Nasdaq Copenhagen: ZEAL; discovered survodutide, out-licensed to Boehringer in 2011)
Asset	Survodutide (BI 456906): subcutaneous glucagon receptor and GLP-1 receptor dual agonist
Indications	Obesity (SYNCHRONIZE-1) and MASLD (SYNCHRONIZE-MASLD)
Data	SYNCHRONIZE-1: up to 16.6% average weight loss at 76 weeks vs 3.2% placebo; SYNCHRONIZE-MASLD met liver endpoints; NEJM and Nature Medicine, June 7, 2026
Royalty structure	High-single-digit to low-double-digit tiered royalties to Zealand on global net sales, plus up to EUR 315M in outstanding milestones
Date	Sun June 7, 2026

Royalty read
Re-rate of	Zealand's high-single-digit to low-double-digit royalty on global survodutide net sales, plus up to EUR 315M in outstanding milestones
Why a re-rate, not an origination	A positive obesity and MASLD Phase 3 package de-risks the regulatory path and the commercial base behind an existing third-party royalty
Read	The window's most royalty-relevant clinical event and a forward monetisation candidate for Zealand, the kind of single-asset, partner-developed line that suits a synthetic or back-book monetisation

AstraZeneca / Eccogene: Elecoglipron (AZD5004 / ECC5004) VISTA and SOLSTICE Phase 2b (ADA 2026)

AstraZeneca (Nasdaq: AZN) presented positive Phase 2b data on elecoglipron (AZD5004 / ECC5004), an oral, small-molecule GLP-1 receptor agonist: the VISTA (obesity) and SOLSTICE (type 2 diabetes) trials both met their primary endpoints, supporting a global Phase 3 (BioStock). Elecoglipron was discovered by Eccogene (Shanghai and Boston) and licensed to AstraZeneca in November 2023 for $185M upfront, up to $1.825B in milestones, and tiered royalties, with AstraZeneca holding global rights outside China.

Term	Detail
Developer / licensee	AstraZeneca (Nasdaq: AZN; ex-China rights; leads global development)
Originator / royalty holder	Eccogene, Inc. (Shanghai and Boston; retains China co-development and co-commercialisation)
Asset	Elecoglipron (AZD5004 / ECC5004): oral, once-daily, biased-signalling small-molecule GLP-1 receptor agonist
Indications	Obesity (VISTA) and type 2 diabetes (SOLSTICE); positioned as a backbone for oral combinations
Data	VISTA and SOLSTICE Phase 2b primary endpoints met; supports global Phase 3; presented at ADA 2026
Royalty structure	Tiered royalties to Eccogene on AstraZeneca's ex-China net sales, plus up to ~$1.825B in outstanding milestones (Nov 2023 license; $185M upfront paid, $60M Phase 2b milestone paid 2024)
Date	ADA 2026 (June 5 to 8)

Royalty read
Re-rate of	Eccogene's tiered royalty on AstraZeneca's ex-China net sales, plus up to ~$1.825B in outstanding milestones
Why a re-rate	Positive Phase 2b obesity and T2DM data clear the bar for a global Phase 3, de-risking the commercial base behind an existing third-party royalty; the window's second after survodutide
Read	A forward monetisation candidate for Eccogene as the asset advances, and a China-originated stream connecting to the W23 Asia-outbound theme
Caveat	The rate band is not public; the royalty is ex-China only (China economics held separately via co-commercialisation); Phase 2b de-risks but does not approve, and the oral GLP-1 field is crowded (Lilly orforglipron, Novo oral semaglutide)

---

Daraxonrasib and Zasocitinib Re-Rates

Two further clinical readouts re-rate third-party economics held outside the developer. The Tango Therapeutics combination data incrementally de-risk Royalty Pharma's daraxonrasib synthetic royalty, an RPRX back-book position originated in June 2025 and last re-rated by the April 2026 RASolute 302 monotherapy Phase 3. Takeda's zasocitinib head-to-head Phase 3 advances the contingent sales milestones owed to Nimbus Therapeutics from the 2022 acquisition, a milestone stream rather than a running royalty.

Tango Therapeutics / Revolution Medicines: Vopimetostat plus Daraxonrasib PDAC Phase 1/2 (Mon June 8)

Tango Therapeutics (Nasdaq: TNGX) reported initial Phase 1/2 data (NCT06922591) for its oral PRMT5 inhibitor vopimetostat combined with Revolution Medicines' RAS(ON) inhibitor daraxonrasib (RMC-6236) in MTAP-deleted, RAS-mutant metastatic PDAC: a 92% objective response rate among 12 response-evaluable patients (9 of 11 confirmed at cutoff) and a 90% six-month progression-free survival rate, supporting advancement into Phase 3 in first-line disease (Tango release, GlobeNewswire). The data cutoff was May 28, 2026.

The tradable economics sit with Royalty Pharma (Nasdaq: RPRX), which holds a synthetic royalty of up to $1.25B on daraxonrasib net sales (five $250M tranches) plus a senior secured loan of up to $750M, agreed June 2025. The second $250M tranche was triggered by the April 2026 RASolute 302 monotherapy Phase 3 readout, taking the current royalty to 4.55% on the first $2B of annual net sales, stepping to as high as 7.80% if the remaining synthetic royalty funding is drawn.

Term	Detail
Sponsor / developer	Tango Therapeutics (Nasdaq: TNGX; sponsors the combination trial; vopimetostat is Tango's PRMT5 inhibitor)
Combination partner	Revolution Medicines (Nasdaq: RVMD; daraxonrasib / RMC-6236, RAS(ON) multi-selective inhibitor)
Royalty holder	Royalty Pharma (Nasdaq: RPRX; synthetic royalty plus senior secured loan on daraxonrasib)
Asset and indication	Vopimetostat plus daraxonrasib in MTAP-deleted, RAS-mutant metastatic PDAC; second and third line
Data	92% ORR (11 of 12 response-evaluable, 9 of 11 confirmed); 90% six-month PFS; median PFS not reached; data cutoff May 28, 2026
Royalty structure	Royalty Pharma: up to $1.25B synthetic royalty (five $250M tranches) plus up to $750M senior secured loan on daraxonrasib (June 2025); current royalty 4.55% on the first $2B of annual net sales, up to 7.80% if fully drawn; royalties begin only after daraxonrasib FDA approval
Date	Mon June 8, 2026

Royalty read
Re-rate of	Royalty Pharma's synthetic royalty on daraxonrasib net sales
Why a re-rate, not an origination	Combination data with a third agent de-risk daraxonrasib's broader commercial profile, indirectly supporting an existing third-party royalty; no new paper is created
Read	An RPRX back-book position rather than new origination; the primary daraxonrasib re-rate was the April 2026 RASolute 302 monotherapy Phase 3 that triggered the second tranche. Vopimetostat itself carries no disclosed third-party royalty
Caveat	The June 8 readout is a Tango-sponsored combination, early and small (12 response-evaluable PDAC patients); the RPRX royalty accrues on daraxonrasib, not on vopimetostat, and begins only on daraxonrasib approval

Takeda / Nimbus: Zasocitinib (TAK-279) LATITUDE Atlas Phase 3 (Thu June 11)

Takeda (NYSE: TAK) reported topline results from LATITUDE Atlas (NCT06973291), a head-to-head Phase 3 in moderate-to-severe plaque psoriasis: zasocitinib (TAK-279), an oral TYK2 inhibitor, was statistically superior to deucravacitinib on the PASI 100 response rate at week 16, with more than 35% of zasocitinib patients achieving complete skin clearance, more than 2.5 times the comparator rate (Takeda release, BioSpace). Takeda plans to begin regulatory submissions in fiscal year 2026.

Takeda acquired zasocitinib through its 2022 purchase of Nimbus Therapeutics' subsidiary Nimbus Lakshmi for $4B upfront, with two contingent milestone payments of $1B each tied to reaching $4B and $5B in annual net sales. The readout advances the asset toward the commercial base on which those milestones depend; the Nimbus economics are sales-gated milestones, not a running royalty.

Term	Detail
Developer	Takeda (NYSE: TAK; leads global development; gained the asset from Nimbus in 2022)
Milestone holder	Nimbus Therapeutics (up to $2B in contingent sales milestones)
Asset and indication	Zasocitinib (TAK-279), oral TYK2 inhibitor; moderate-to-severe plaque psoriasis
Data	LATITUDE Atlas (606 patients); PASI 100 at week 16 statistically superior to deucravacitinib; more than 35% complete skin clearance, more than 2.5 times comparator; separation from week 8
Milestone structure	Two $1B contingent payments to Nimbus at $4B and $5B in annual net sales (2022 acquisition: $4B upfront)
Date	Thu June 11, 2026

Royalty read
Re-rate of	Nimbus's contingent sales milestones on zasocitinib (not a running royalty)
Why a re-rate	A superiority readout against the class leader strengthens the commercial trajectory toward the $4B and $5B sales thresholds that gate the Nimbus milestones
Read	A milestone re-rate, not a tradable royalty; the Nimbus payments are large but distant and sales-contingent, with no running rate to monetise
Caveat	Milestones trigger only at $4B and $5B in annual net sales, years from launch; head-to-head superiority is topline only, with full data and safety detail pending

---

Standard disclaimer

This Weekly Term Sheet is provided for informational purposes only. It does not constitute investment advice, an offer to sell or a solicitation of an offer to buy any security, or a recommendation regarding any investment. Data and disclosures are sourced from public company filings, press releases, and credible secondary reporting. Capital for Cures AG does not warrant the accuracy or completeness of information presented. Readers are advised to consult primary source documentation before making any investment, partnership, or commercial decision. Capital for Cures AG and its principals may hold positions in companies referenced.